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1. Introduction 
1.1 Drug discovery from marine-derived fungi 
 
Natural products are produced by all living organisms, and as primary metabolites serve the 
basic survival. In medicinal chemistry natural products are defined as secondary metabolites, 
that are biosynthesized for their biological function, e.g. to defend the producer against 
predators or competitors. They are known to be essential in pharmacology for the search and 
development of novel drugs. This is due to their bewildering diversity of carbon skeletons and 
scaffolds, resulting in a remarkable structural complexity. In the period of 1981 to 2014 over 
50 % of 1562 new approved drugs were natural products, natural product derivatives or 
synthetic compounds with natural product derived origin (Newman und Cragg 2016) (Figure 
1). This demonstrates the importance of natural product drugs for therapy, and also their 
usefulness as lead compounds that can be optimized to gain novel drugs.  
 
 
 
Figure 1: New approved drugs from 1981-2014 and their origin: n = 1562, adapted from 
Newmann and Cragg, 2016 
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The most prominent producers of therapeutic natural products are three groups of organisms: 
plants, bacteria and fungi.  
Plants were used for thousands of years for medicinal purposes, e.g. in the Traditional 
Chinese Medicine (TCM). The WHO estimated that approximately 65% of the population of 
the world predominantly relied on plant-derived traditional medicines for their primary health 
care (Fransworth et al. 1985). In 1971, Paclitaxel (Taxol®), as seen in Figure 2, was firstly 
isolated from the pacific yew tree (Wani et al. 1971). It is an inhibitor of the mitosis process 
in cells by interfering with the normal function of microtubule breakdown. It binds to β–
tubulin thus arrests microtubule function. This way cells cannot use their cytoskeleton in a 
flexible manner (McGrogan et al. 2008). The semi-synthetic analog docetaxel (Taxotere®) 
and later the third generation taxane cabazitaxel (Jevtana®), which is approved for the 
treatment of hormone-refractory prostate cancer (Galsky et al. 2010), are successful examples 
of plant-based antitumor drugs.  
Within the group of bacteria, actinomyces, myxobacteria and cyanobacteria are playing a 
major role as natural product producing organisms. Bacteria of the genus Streptomyces, 
produce, e.g. antitumor agents interacting with DNA like daunorubicin  (Minotti et al. 2004). 
The myxobacterium Sorangium cellulosum produces epothilone B (Figure 2). A semi-
synthetic derivative thereof is ixabepilone, which acts as microtubule-stabilizing agent like 
the taxanes described above and is used for the treatment of metastatic breast cancer since 
2007 (WHO 2007) (Mani et al. 2007).     
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Figure 2: Examples of antitumor lead structures and drugs from plants and bacteria 
 
 
 
 
1.2 Drugs of fungal origin 
 
Fungi are a vast group of organisms, which produce a wide range of pharmaceutically 
significant compounds, belonging to all structural classes.  
A most important fungal metabolite is the immunosuppressant drug mycophenolic acid 
(Figure 3). Already isolated in 1893, it was approved by the FDA in 1995 and is used for the 
prophylaxis of organ rejection in patients receiving an allogeneic renal transplant (FDA 
2009). The dosage form is the prodrug mycophenolat-mofetil, which is metabolized in the 
body to the desired mycophenolic acid.  
Fusidic acid (Figure 3) is a tetracyclic terpenoid compound from the fungus Fusidium 
coccineum, firstly investigated in the early 1960s as an antibacterial agent with strong in vitro 
activity against Gram-positive bacteria (Godtfredsen et al. 1962). The growing resistance 
posed by methicillin resistant Staphylococcus aureus (MRSA) and other staphylococcal 
infections has led to a revived interest in the use of fusidic acid in recent years. In vitro assays 
with fusidic acid showed efficacy against most staphylococcal infections, including those 
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caused by MRSA, vancomycin-intermediate S. aureus and most coagulase-negative 
staphylococci (Howden and Grayson 2006).  
The statine lovastatin, isolated from Aspergillus terreus, is used as a cholesterol lowering 
agent and served also as a lead structure for e.g. pravastatin, a second generation drug thereof 
(Figure 3). Statins inhibit the activity of (3S)-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-
CoA) reductase by occupying a portion of the binding site of HMG-CoA, thus blocking 
access of this substrate to the active site. Near the carbonyl terminus of the reductase, several 
catalytically relevant residues are disordered in the enzyme-statin complex. HMG-CoA 
reductase catalyzes the formation of mevalonate, which is the limiting step in hepatic 
cholesterol synthesis.  
Figure 3: Examples of drug and drug lead structures from fungi 
 
 
 
 
1.3 Marine-derived fungi and their associated metabolites 
 
Besides the terrestrial fungi discussed above, fungal strains are also found in various, often 
underexplored habitats and their metabolomes are judged as valuable sources of bioactive 
compounds. The study of marine fungi has been mostly neglected for different reasons, e.g. 
the doubt of the existence of truly marine fungi or their low abundance in the environment. 
This attitude changed in recent years due to the fact that structurally diverse secondary 
metabolites were obtained from marine-derived fungi, and thus a considerable number of 
pharmaceutically relevant bioactivities and possible candidates for the development of new 
drugs were found (Imhoff 2016). Whereas in the whole year 1992 only 15 metabolites were 
reported from marine-derived fungi, the systematic chemical characterization of fungi from 
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the marine environment has now provided a large number of natural products from this 
source, some of them with clinically relevant pharmacological activity (Jin et al. 2016).  
Most of the published data have a focus on just a few genera: Aspergillus, Cladosporium, 
Fusarium and Penicillium (Imhoff 2016). Many of these fungi are excellently adapted to the 
marine habitat, e.g. deep-sea hydrothermal ecosystems, algae or sponges. As obvious from the 
above mentioned genera many of the marine-derived fungal metabolites are similar to those 
of their terrestrial counterparts. However, examples like gymnastatin G with an unusual 
carbon skeleton indicate that marine fungal strains possess distinct biosynthetic capabilities 
(Bugni and Ireland 2004) (Figure 4). Gymnastatin G contains a unique bicyclo[3.3.1]nonane 
ring, and was found to exhibit potent growth inhibition against P388 leukemia cancer cell 
lines with an ED50 of 0.03 µg/ml (Amagata et al. 2006) (Figure 4).  
Alterporriol L, which was isolated from the marine-derived fungus Alternaria sp. showed 
modest cytotoxicity against two human breast cancer cell lines (MDA-MB-435 and MCF-7) 
with IC50 values of 13.1 to 20.0 µM (Huang et al. 2011) (Figure 4). The cytotoxic effect was 
due to apoptosis and necrosis. The dose-dependent manner of cell death by the increased 
levels of cytosolic free calcium and the reactive oxygen species production as well as induced 
loss of mitochondrial membrane potential suggested that alterporriol L caused major stress in 
breast cancer cells by destroying mitochondria (Huang et al. 2012). Furthermore, a mixture of 
derivatives including alterporriol G and H showed considerable cytotoxicity against L5178Y 
mouse lymphoma cells with an EC50 value of 2.7 µg/ml (Debbab et al. 2009).  
Marine algicolous fungi produce unique and complex structural metabolites with a broad 
spectrum of biological activities, e.g. cytotoxic or antioxidant effects. Gao et al. investigated 
the new polyoxygenated steroids penicisteroids A and B, which were obtained from the 
extract of Penicillium chrysogenum QEN-24S, an endophytic fungus isolated from an 
unidentified marine red algal species of the genus Laurencia (Figure 4). Penicisteroid A, a 
structurally new steroid having four hydroxyl and a C-16-acetoxy group, displayed potent 
inhibitory activity against the pathogenic fungus Aspergillus niger, as well as selective 
cytotoxicity against cancer cell lines, e.g. an IC50 of 15 µg/ml towards HeLa cells. Although 
steroids are one of the most abundant classes of natural products reported so far, only two 
structurally similar steroids containing a 11-OH and 16-OAc group have been reported (Mori 
et al. 2003a; Mori et al. 2003b; Igarashi et al. 2002). It is assumed, that the hydroxyl group at 
C-6 in the B ring is essential for the cytotoxicity, since the derivative without the hydroxyl 
group showed no activity (Gao et al. 2011).  
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Figure 4: Examples of natural products from marine-derived fungi with cytotoxic activity 
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1.4 Phytopathogenic fungi with a focus of Stemphylium spp.  
 
In this study, the focus is on natural products produced by a fungus from the marine habitat, 
i.e. Stemphylium globuliferum isolated from the alga Petalonia zosterifolia. This alga-derived 
fungus is in the literature described for its phytotoxicity (Koike et al. 2013). Phytopathogenic 
fungi are rarely investigated for their bioactive compounds, but clearly have the potential to 
yield new lead structures. 
Fungal damages to plants and especially agricultural plants is widely observed, e.g. 
Neonectria ramulariae, causes seed rot in japanese beech (Hirooka et al. 2012). Seeds of this 
plant (Fagus crenata) are eaten raw or cooked. N. ramulariae is producing pyrrospirones A 
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and B (Figure 5), which exhibit cytotoxicity and induced apoptosis of promyelocytic 
leukemia cells at a concentration of 30 µM (Shiono et al. 2008). Pyrrocidine A and B, 
derivatives of pyrrospirones, showed potent antibiotic activity against MRSA at MIC values 
of 2 and 4 µg/ml, respectively, as well as weaker activity towards Candida albicans and 
Streptococcus pneumoniae (He et al. 2002).  
 
Figure 5: Examples of bioactive compounds from phytopathogenic fungi  
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The here investigated fungus S. globuliferum is a mold fungus and belongs to the 
Pleosporaceae, and was firstly described by Simmons in 1969 (Simmons 1969). Previously, 
the focus of research on Stemphylium spp. targeted the prevention of agricultural damages 
caused by these organisms. Stemphylium spp. are responsible for the leaf spot of lettuce, but 
also have been reported to infect different hosts worldwide to cause leaf spot symptoms (e.g. 
eggplant, pepper and tomato) (Nasehi et al. 2012, 2014) (Gannibal 2013) (Barash et al. 1975) 
(Andersen and Frisvad 2004). The Stemphylium leaf spot disease, caused by S. vesicarium 
and the closely related S. botryosum leads to the so called purple spot disease on Asparagus 
officinalis, which is the most important disease in German asparagus growing regions (Graf et 
al. 2016). Fungicides like epoxiconazol or prochloraz inhibit fungal ergosterol biosynthesis 
and can be used for prevention of the disease (Zapf et al. 2011). 
Stemphyloxin I is a phytotoxin, which was firstly isolated from S. botryosum. This fungal 
metabolite is a natural compound possessing an enol group on C-12 (Figure 6), which may be 
in equilibrium with an aldehyde function via keto-enol-tautomerism. Injections of 
stemphyloxin I into tomato leaflets caused necrotic spots and wilted the whole leaf with 
visible symptoms beginning at 2.7 µM. A derivative of stemphyloxin I, where the enol group 
is methylated, revealed a reduction of approximately 50 times in inhibitory activity as 
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compared to the toxin (Barash et al. 1982). The tricyclic compound stemphyloxin II is 
approximately 100 times weaker compared to stemphyloxin I (Manulis et al. 1984).  
 
Figure 6: Stemphyloxin I and II 
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Altersolanol A, which was found in S. globuliferum has an effect on K562 cells (Figure 7), 
with IC50 values of 4 and 2.5 µM after 24 h and 48 h exposure, respectively. The anti-tumoral 
potential is linked to its pro-apoptotic and anti-invasive activity, which is caused by the 
inhibition of NF-κB transcriptional activity. This biological effect is related to the p-quinone 
moiety of the molecule (Teiten et al. 2013). The significance of a quinone moiety in potential 
anticancer molecules was also reported for the plant-derived anthraquinone parietin, which 
induces apoptosis in human cervical carcinoma HeLa cells by activating the caspase-3 
pathway and forming reactive oxygen species (Wijesekara et al. 2014).   
 
Figure 7: Altersolanol A from S. globuliferum 
 
 
 
Stemphylium spp., is also known for the production of the phytotoxin stemphol (Figure 8). It 
is a 2,5-dialkylated resorcinol with a butyl- and pentyl-chain attached to the aromatic ring in 
the C-2 and C-5 position, respectively. It has significant inhibitory activity towards the 
phylogenetically related fungus Pleospora herbarum. At 400 µg/ml stemphol tested, more 
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than 63% inhibition of self growth was observed for P. herbarum (Marumo et al. 1985). 
Furthermore, stemphol showed antibacterial activity against B. subtilis and S. aureus, as well 
as the yeast Schizosaccharomyces pombe and the plant pathogenic fungus Mucor hiemalis 
(Achenbach et al. 1979).  
In bacteria, stemphol is biosynthetically produced by connecting a β-keto-acyl precursor with 
an α,β-unsaturated acyl precursor followed by oxidation to form a dialkylresorcinol. 
Compared to the monoalkylresorcinols, which are synthetized by an iterative type III 
polyketide synthase (PKS III) that performs multiple catalytic reactions, PKSs responsible for 
dialkylresorcinol production only catalyze one reaction, i.e. the connection of the above 
mentioned precursors (Schöner et al. 2015).  
However, a fungal gene cluster responsible for stemphol formation has not been found yet. 
This is in contrast to bacteria, for which such biosynthetic gene cluster are known (Schöner et 
al. 2015).  
 
1.5 Resorcinol and its mono,- and dialkylated derivatives 
 
The S. globuliferum derived stemphol (Figure 8) discussed in this thesis is part of a whole 
class of resorcinol derivatives. 
Resorcinol and its mono and dialkylated derivatives display a broad spectrum of biological 
activities (Figure 8). Resorcinol is an ingredient in skin protectant formulations like Resinol® 
or Clearasil®, and it is used for the treatment of psoriasis or seborrheic dermatitis. Due to high 
contents of resorcinol in argan oil this is utilized in the traditional Moroccan medicine against 
acne juvenile and flaking of the skin, but also against rheumatism and for the treatment of 
burns (Charrouf and Guillaume 2007) (El Babili et al. 2010).  
Monoalkylated 4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect 
with cisplatin, leading to a significantly decreased tumor growth rate in mice with cancer 
(Kim et al. 2011). In the past, it has been mainly used for antiparasitic purposes, until much 
more effective antiparasitic agents have been developed (Rabbani et al. 1985) (Pink et al. 
2005). 5-Alkylated resorcinols showed moderate antibacterial and antifungal activity 
(Achenbach et al. 1979). 
The 2,5-dialkylated derivatives like stemphol were shown to have an even broader 
antimicrobial spectrum. One example is DB-2073, where a propyl chain at the C-2 position 
and a hexyl chain at the C-5 position, are attached to the benzene ring. DB-2073 was firstly 
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isolated from Pseudomonas sp. B-9004 from a soil sample (Kanda et al. 1975) and its total 
synthesis is known (Covarrubias-Zúñiga et al. 2003). It is active against mycobacteria, yeasts, 
fungi and Gram-positive bacteria (e.g. MIC 25 µM towards St. aureus) (Kanda et al. 1975). 
DB-2073 has free radical scavenging activity preventing lipid peroxidation. At an IC50 of 2.74 
µM concerning lipid peroxidation induced by free radicals, DB-2073 is much more active 
than flunarizine (IC50: 55.0 µM). The latter is a migraine protective drug with free radical 
scavenging activity, and is less active than butylated hydroxytoluene (BHT, IC50: 2.4 µM), a 
common antioxidant. Similar results were shown for resorstatin with an IC50 of 2.06 µM 
(Kato et al. 1993). Besides the free radical scavenging activity of resorstatin (Figure 8), it has 
a weak antibacterial activity towards B. subtilis (Kato et al. 1993). Resorcinin, a derivative 
thereof, stimulates the proliferation of NIH 3T3 mouse fibroblasts cells at concentrations from 
0.2 µg/ml to 2 µg/ml. The activity is slightly higher than that for a monoalkyl long chain 
reference. Isopropylstilbene (Figure 8), which has antiproliferative activity (Buscato et al. 
2013) is another example for the structural and biological diversity of this class of molecules. 
Regarding resorcinol derivatives, a recent review by Schöner et al. summarizes occurrence, 
structural diversity, bioactivity and biosynthesis of these natural products (Schöner et al. 
2015). 
 
Figure 8: Resorcinol and its mono,- and dialkylated derivatives 
 
  
 
 Scope of the present study   
 
11
2.  Scope of the present study 
 
The search for compounds possessing bioactivity and consequently pharmaceutical relevance 
is in high demand. Marine-derived fungi are a group of microorganism producing a wide 
range of pharmaceutically significant compounds belonging to different structural classes. 
This source of bioactive products is still very little investigated. This study focusses on the 
marine-derived fungus Stemphylium globuliferum strain No. 384, isolated from the alga 
Petalonia zosterifolia, and collected at the Baltic Sea, for the identification and aims of 
possible new lead structures for pharmaceutically purposes. The here investigated fungus is 
known for its phytopathogenity resulting massive agricultural damages.   
In this study the main aspect lies on the investigation of this fungus from a different point of 
view. Is it possible to turn the known negative properties into positive pharmacological 
aspects? Furthermore the isolation from the unusual salt water habitat underlies the possibility 
to gain new bioactive natural products from this poorly investigated research area.  
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3.      Materials and methods 
3.1 Origin, isolation and taxonomy of the fungus 
 
The endophytic fungal strain, described in this study, was obtained from the fungal culture 
collection of Professor G. M. König (Institute for Pharmaceutical Biology, University of 
Bonn), and was isolated by Ekaterina Egereva using an indirect isolation method. The alga 
sample was rinsed three times with sterile H2O. After surface sterilization with 70% EtOH for 
15 s, the alga was rinsed in sterile artificial seawater (ASW). Subsequently, the alga material 
was aseptically cut into small pieces and placed on agar plates containing isolation medium: 
agar 15 g/L, ASW 800 mL/L, glucose 1 g/L, peptone from soymeal 0.5 g/L, yeast extract 0.1 
g/L, benzylpenicillin 250 mg/L, and streptomycin sulfate 250 mg/L. The fungus growing out 
of the alga material was separated on biomalt medium (biomalt 20 g/L, agar 10g/L, ASW 800 
mL/L) until the culture was pure. The isolated fungus was identified by C. Decock and P. 
Massart, BCCM/MUCL, Catholic University of Louvain, Belgium. A specimen is deposited 
at the Institute for Pharmaceutical Biology, University of Bonn, strain number 384.  
3.2 Cultivation of the fungal strain 
 
For the screening examination, fungal strains were cultivated in petri dishes for fourty days on 
three different media: (a) biomalt salt agar medium, (b) potato dextrose agar medium, and (c) 
malt peptone yeast medium. For pre-cultivation, the fungal strains were inoculated on petri 
dishes with biomalt agar medium and incubated at 25 °C for 4 weeks. The large scale 
cultivation of the fungi was processed in 40 Fernbach flasks at room temperature and 
permanent light using three solid media (250 ml each), e.g. biomalt salt agar medium, potato 
dextrose agar medium, or potato dextrose with 0.1 % Sodiumacetate medium.  
 
(a) Biomalt agar medium: 20 g/L biomalt, 15 g/L agar and 1 L ASW. 
(b) Malt-yeast agar medium: 4 g/L yeast extract, 10 g/L malt extract, 4 g/L glucose, 15 g/L 
agar and 1 L ASW, pH 7.3. 
(c) Potato dextrose agar medium: 15 g/L potato dextrose broth, 15 g/L agar and 1 L ASW. 
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Artificial seawater (ASW): [g/L] KBr (0.1), NaCl (23.48), MgCl2 × 6 H2O (10.61), CaCl2 × 2 
H2O (1.47), KCl (0.66), SrCl2 × 6 H2O (0.04), Na2SO4 (3.92), NaHCO3 (0.19) and H3BO3 
(0.03). 
 
3.3 Extraction of the fungal material 
 
Cultivation medium and mycelia were homogenized using an Ultra-Turrax T45 apparatus and 
extracted three times with ethyl acetate.  
 
3.4 Chromatography 
3.4.1 Vacuum liquid chromatography (VLC) 
 
Sorbents for VLC were silica gel 60 (0.063-0.200 mm, Merck) or silica gel 60 (0.040-0.063 
mm, Merck). Columns were wet-packed under vacuum, using PE or dichloromethane for 
normal-phase, and MeOH for reversed-phase conditions. Glass wool layer above the sorbent 
material was used to protect the sorbent material against disturbance. Before applying the 
sample solution, the columns were equilibrated with the first designated eluent.  
 
3.4.2 High performance liquid chromatography (HPLC) 
 
Preperative HPLC was carried out using four different systems. A: Waters system, controlled 
by Waters Millenium software, consisting of a 600E pump, a 996 photodiode array detector, 
and a 717 plus autosampler; B: Merck-Hitachi HPLC system Model D-7000 Chromatography 
Data Station Software HPLC system Manager Version 4.0 software, consisting of L-6200A 
pump, D-6000A interface and L4500 photodiode array detector; C: HP ChemStation for 
LC.Rev.A.06.03[909] software, consisting of a L-7100 Merck Hitachi pump and a HP-series 
1050 detector; D: Waters System 1525µ  equipped with Binary pump and 2998 photodiode 
array detector and Breeze 2 software, 2008; E: Reverleris Grace X2 flash-chromatography 
system equipped with pump, autosampler, UV- and RI-detector.  
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Columns used were either a: Knauer Si Eurospher-100 (5 µm, 250 x 8 mm), b: Knauer C18 
Eurospher-100 (5 µm, 250 x 8 mm), c: Macherey-Nagel Nucleodur 100-5 C18 (5 µm, 250 x 
4.6 mm), d: Macherey-Nagel Nucleoshell C18 (5 µm, 250 x 4.6 mm), e: Phenomenex Kinetex 
C18 (5 µm, 250 x 4.6 mm) or Grace Reveleris SRC C18 cartidge (12g). 
3.5 Structure elucidation 
 
Structures were elucidated mainly using one and two dimensional NMR techniques in 
combination with various MS methods. Optical rotation data as well as the UV and IR 
spectroscopic properties provided additional information. The relative and absolute 
stereochemistry of the new compounds was assigned using NOESY experiments. The identity 
of isolated compounds in comparison to previously published structures was jugded on 1H 
NMR und 13C NMR data and other spectroscopic data, as well as specific optical rotation. In 
addition, calculated NMR shifts of the assumed structures with ACD (Labs-software, 2006) 
assisted in the elucidation of most structures. Based on literature searches, using MarinLit 
database®, Sci Finder database® and AntiBase database®, the structures were classified as 
new, if they could not be found in any of these databases. 
 
3.5.1 NMR spectroscopy 
 
All NMR spectra were recorded using either a Bruker Avance 300 DPX operating at 300 
MHz (1H) and 75 MHz (13C) or a Bruker Ascend 600 spectrometer operating at 600 MHz for 
(1H) and 150 MHz for (13C) respectively. NMR spectra were processed using Bruker 1D 
WIN-NMR, 2D WIN-NMR or XWIN-NMR Version 2.6, 3.1 and 3.5 software, or Bruker 
TopSpin software package Version 1.3. Spectra were recorded in CDCl3, acetone-d6 or 
CD3OD and were referenced to residual solvent signals with resonances at δH/C 7.26/77.0 
(CDCl3), 2.04/29.8 (acetone-d6) and 3.35/49.0 (CD3OD). Multiplicity of carbons was deduced 
by 13C and DEPT experiments. Structural assignments were based on spectra resulting from 
one or more of the following NMR experiments: 1H, 13C, DEPT 135, 1H-1H-COSY, 1H-13C 
direct correlation (HSQC), 1H-13C long range correlation (HMBC), 1H-1H Overhauser 
Enhancement Spectroscopy (NOESY). Two dimensional NMR measurements were guided by 
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Dr. Stefan Kehraus (Institute for Pharmaceutical Biology, University of Bonn, Germany) or 
Dr. Sedana Nozinovic (Institute for Inorganic Chemistry, University of Bonn, Germany).  
 
3.5.2 Mass spectrometry 
 
HPLC-ESIMS (referred to as LC-MS or HPLC-MS) measurements were performed by 
Ekaterina Egereva (Institute for Pharmaceutical Biology, University of Bonn, Germany) 
employing an Agilent 1100 Series HPLC including DAD, with RP C18 column (Macherey-
Nagel Nucleodur 100, 125 mm x 2 mm, 5µm) and gradient elution (0.25mL/min, NH4Ac 
buffer 2 mmol, from MeOH 10: H2O 90 in 20 min to 100% MeOH, then isocratic for 10 min), 
coupled with an API 2000, Triple Quadrupole LC/MS/MS, Applied Biosystems/MDS Sciex 
and ESI source. The analyzed extracts, fractions and pure compounds were solved in MeOH 
(1 mg/ml) for injection into the HPLC-ESIMS system.  
HPLC-MS/MS experiments were recorded on a micrOTOF-Q mass spectrometer (Bruker) 
with ESI-source coupled with a HPLC Dionex Ultimate 3000 (Thermo Scientific) using a 
EC10/2 Nucleoshell C18 2.7 µm column (Macherey-Nagel). The column temperature was 
25°C. MS data were acquired over a range from 100-3000 m/z in positive mode. Auto 
MS/MS fragmentation was achieved with rising collision energy (35-50 keV over a gradient 
from 500-2000 m/z) with a frequency of 4 Hz for all ions over a threshold of 100. HPLC 
begins with 90 % H2O containing 0.1% acetic acid. The gradient starts after 1 min to 100%. 
Acetonitrile (0.1% acetic acid) in 20 min. 5 µl of a 1mg/ml sample solution was injected to a 
flow of 0.3 ml/min. 
 
3.5.3 UV measurement 
 
UV spectra were recorded on a Perkin-Elmer Lambda 40 with UV WinLab Version 2.80.03 
software, using 1.0 cm quartz cells. Compounds were measured in methanol, chloroform or 
acetonitrile. The molar absorption coefficient was determined in accordance with the Beer-
Lambert Law: 
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A  : absorption at peak maximum 
c : concentration  
ε : molar extinction coefficient 
d  : layer thickness of solution 
 
3.5.4 IR spectroscopy 
 
IR spectra were recorded using a Perkin-Elmer FT-IR Spectrum BX spectrometer interfaced 
with a Specac Golden Gate Diamond ATR system. Analysis and reporting were performed 
with Spectrum v3.01 software. 
 
3.5.5 Optical rotation 
 
Optical rotation measurements were conducted on a Jasco model DIP-140 polarimeter (1 dm, 
1 cm3 cell) operating at λ = 589 nm corresponding to the sodium D line at room temperature. 
Specific optical rotation [ ]TDα  was calculated pursuant to: 
 
[ ]
lc
100
  
T
D
⋅
⋅
=
α
α  
 
α  : rotation angle in degree 
T  : temperature [°C] 
D : sodium D line at λ = 589 
c  : concentration [g/100 mL] 
l  : cell length [dm] 
The compounds were dissolved either in MeOH or chloroform. The rotation angles α were 
determined as an average value based on at least 10 measurements. 
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3.5.6 CD spectroscopy 
 
CD spectra were recorded in MeOH or CH3CN at room temperature using a JASCO J-810-
150S spectropolarimeter with the kind help of Carsten Siering and Prof. Dr. S. Waldvogel, 
Kekulé-Institute for Organic Chemistry and Biochemistry, University of Bonn, Germany. The 
path length was l = 0.1 cm. The CD (circular dichroism) was measured as ellipticity Θ (in 
mdeg, millidegrees) and subsequently converted into the molar ellipticity [Θ]M and finally 
into ∆ε in accordance to the following equation, taken from Hesse, Meier and Zeeh, 1995: 
 
 
 
 
Θ = ellipticity [degrees] 
[Θ]M = molar ellipticity [degrees x cm2/dmol] 
c = concentration [mg/mL] 
l = path lengh [dm] 
M = molecular weight [g/mol] 
 
3.5.7 Molecular modeling 
 
All models were calculated employing conformation search (Boltzman jump) and a standard 
force field as implemented in the Cerius2 4.0 (MSI) molecular modeling software package. 
Models were further refined with 1500 iterations of minimization. Calculations were 
performed using a Silicon Graphics O2 workstation (Irix 6.5.6). 
 
3.6 Evaluation of biological activity 
 
3.6.1 Agar diffusion assay in the working group of Prof. König 
 
[Θ]M = 
ΘxM
100 xc x l
= 3.3 x103 x∆ε
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Antimicrobial tests of extracts and isolated pure compounds were performed by Edith Neu 
(Institute for Pharmaceutical Biology, University of Bonn) following the method described by 
Schulz et al. (Schulz et al. 1995). The bacteria Bacillus megaterium de Bary (Gram-positive) 
and Escherichia coli (Migula) Castellani & Chambers (Gram-negative), the fungi 
Microbotryum violaceum (Pers.) Roussel (Ustomycetes), Eurotium rubrum (formerly E. 
repens) König, Spieckermann & Bremer (Ascomycetes) (all from DSMZ; Braunschweig, 
Germany) and Mycotypha microspora Fenner (Zygomycetes) (kindly provided by B. Schulz, 
Institute of Microbiology, University of Braunschweig, Germany) were used as test 
organisms. Sample solutions contained 1 mg/ml per test sample. 50 µL (equivalent to 50 µg) 
of each solution were pipetted onto a sterile antibiotic filter disk (Schleicher and Schell 2668), 
which was then placed onto the appropriate agar medium and sprayed with a suspension of 
the test organism. Growth media, preparation of spraying suspensions, and conditions of 
incubation were carried out according to Schulz et al. (Schulz et al., 1995). Growth inhibition 
was defined as follows: growth of the appropriate test organism was significantly inhibited 
compared to a negative control; total inhibition: no growth at all in the appropriate zone. 
Benzyl penicillin (1 mg/ml MeOH), streptomycin (1 mg/ml MeOH) and micronazole (0.5 
mg/mL DCM) were used as positive controls.  
 
3.6.2 Agar diffusion assay in the working group of Prof. Sahl 
 
Antimicrobial tests of extracts and isolated pure compounds were performed by Michaele 
Josten (Institute for Medicinal Microbiology, University of Bonn). Culture plates (5% sheep 
blood Columbia agar, BD) were overlaid with 3 ml Tryptic soy soft agar, inoculated with 
TSB (Tryptic soy broth, Oxoid) growth suspension of the bacteria to be tested. Compounds 
were diluted to a concentration of 1 mg/ml (Syringomycin 0.5 mg/ml) with DMSO and 3 µL 
of this dilution were placed on the surface of the agar. Compounds diffuse into the agar and 
the size of the inhibition zone was measured after 24 hours incubation at 37 °C.  
 
MIC determinations 
 
MIC determinations were carried out in microtiter plates. Strains were grown in half-
concentrated Mueller-Hinton broth (Oxoid). MICs with serial twofold dilution steps were 
performed (1:2). Bacteria were added to give a final inoculum of 105 CFU/mL in a volume of 
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0.2 mL. After incubation for 24 hours at 37 °C the MIC was read as the lowest compound 
concentration causing inhibition of visible growth.  
 
3.6.3 Antiprotozoal activity 
 
The antiprotozoal tests were performed by Dr. M. Kaiser (Swiss Tropical Institute, Basel, 
Switzerland). Antiplasmodial activity was determined against the K1 strain of Plasmodium 
falciparum, using a modified [3H] hypoxanthine incorporation assay. Briefly, infected human 
erythrocytes were exposed to serial drug dilutions in microtiter plates for 48 h at 37° C in a 
gas mixture with reduced oxygen and elevated CO2. [3H] hypoxanthine was added to each 
well and after further incubation for 24 h the wells were harvested on glass fiber filters and 
counted in a liquid scintillation counter. From the sigmoidal inhibition curve the IC50 value 
was calculated. Chloroquine was used as positive control in each test series. 
Activity against Trypanosoma brucei rhodesiense (strain STIB 900), the causative agent of 
African sleeping sickness, was evaluated according to Räz et al. (Räz et al. 1997). Parasites 
were grown axenically in culture medium supplemented with horse serum. Following a 3-day 
exposure to test compounds, the viability of tryptomastigote parasites was quantified using 
the dye Almar Blue® by monitoring the reductive environment of living cells. 
Fluorescence development was expressed as percentage of the control, and IC50 values were 
calculated. Melarsoprol was included as positive control. 
 
Activity against Trypanosoma cruzi, the causative agent of Chagas disease, was determined 
according to Buckner and co-workers (Buckner et al .1996).  Briefly, the strain Tulahuen C4 
of T. cruzi, which had been transfected with the galactosidase lac-Z gene, was cultivated for 4 
days on rat skeletal myoblasts (5 % CO2, 37° C) in the presence of drug. For measurement of 
the IC50 the substrate chlorophenol red-β-D-galactopyranoside was added. The colour reaction 
that developed during the following 2-6 h was quantified photometrically employing an 
ELISA reader. Benznidazole was included in each test series as positive control. 
 
Evaluation of antileishmanial activity was carried out in mouse peritoneal macrophages. The 
ratio of infection with Leishmania donovani (strain MHOM-ET-67/L82), the causative agent 
of Kala-Azar disease, was determined microscopically after exposure to test compounds, 
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incubation and staining with Giemsa. IC50 values were calculated by linear regression. 
Miltefosine was used as positive control.  
Cytotoxicity was evaluated in rat skeletal myoblasts (L6-cells), using podophyllotoxin as 
positive control. 
 
3.6.4 Antichlamydial activity 
 
3.6.4.1      Determination of minimal inhibitor concentration 
 
 Determination of the minimal inhibitor concentration (MIC) of antibiotics for C. trachomatis 
was performed in cell culture using fluorescence-microscopy based assays. 200 µl of Hep2 
host cells suspension were incubated for 48 h in 96 µ well plates (Ibidi, Germany) followed 
by the infection with C. trachomatis D/UW-3/CX supernatant. After 2 h of incubation at 37 
°C, 5% CO2 medium was removed and 100 µl fresh medium, supplemented with serially 
diluted concentrations of the compounds, were added. Cultures were incubated for 30 h at 37 
°C, 5% CO2 and afterwards fixed with ice cold methanol for 5 min. Subsequently, plates can 
be stored at -70 °C. Samples were stained using fluorescein-conjugated antibodies specific for 
chlamydial lipopolysaccharide. Therefore Pathfinder Chlamydia Conformation System 
(BioRad, Germany) was diluted 1:5 with PBS buffer and 100 µl were added to each well and 
incubated for 30 min at 37 °C. Afterwards, the plate was incubated for 1 min with additionally 
3 mg/ml DAPI followed by 2 washing steps with PBS, 10 min each. Finally, samples were 
analyzed via fluorescence microscopy. It is important during staining and analyzing procedure 
to protect plates from sunlight in order to avoid bleaching. 
 
3.6.4.2      Cell viability assay 
 
Determination of the MIC using a fluorescense based assay is expensive and time consuming, 
that is why Osaka et al. recommend using a simple resazurin-based assay for measuring 
chlamydial infections (Osaka und Hefty 2013). The Alamar blue assay (Life Technologies, 
Germany) is a method utilizing the indicator dye resazurin for estimating the number of viable 
cells present in 96 well plates. The principle of the assay consists in the fact that viable cells 
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retain the ability to reduce the darkblue resazurin into the pink highly fluorescent resorufin, 
whereby either fluorescence or absorbance can be used to record results. In contrast, 
nonviable cells rapidly lose metabolic capacity and are unable to convert resazurin in 
resorufin.  
The fact, that chlamydiae are released through cell lysis and thereby destroying the host cell 
makes it possible to use the alamar blue assay for measuring the level of infection and to 
figure out whether an antibiotic is active against these bacteria.  
After incubation of non-infected or infected Hep2 cells medium was removed and the 
monolayer was washed twice with HBSS. Subsequently, 10 µl of the ready to use alamar blue 
solution was added to 100 µl HBSS. Samples were incubated for 1 h at 37 °C and 5% CO2 
followed by measuring the absorbance at 570 nm.  
Moreover, this assay is suitable to determine cytotoxicity of the compound on non-infected 
host cells. Therefore, 50000 Hep2 cells were incubated for 48 h, subsequently the compound 
of interest was added and incubated for additional 30 h. The following washing, incubation 
and measuring steps were performed as described above. 
 
 
3.6.5 Radioligand binding studies at CB1 and CB2 receptors 
 
Competition binding assays were performed using the CB agonist radioligand [3H](−)-cis-3-
[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP 
55,940, final concentration 0.1 nM). As a source for human CB1 and CB2 receptors membrane 
preparations of Chinese hamster ovary (CHO) cells stably expressing the respective receptor 
subtype were used (30 µg of protein/well for CB1 and 8 µg of protein/well for CB2-receptor 
preparations). Stock solutions of the test compound were prepared in DMSO. The final 
DMSO concentration in the assay was 2.5%. After addition of 15 µL of the test compound in 
DMSO, 60 µL of [3H]CP 55,940 solution in assay buffer, and 60 µL of membrane preparation 
to 465 µL of assay buffer (50 mM TRIS, 3 mM MgCl2, 0.1% Bovine Serum Albumine 
(BSA), pH 7.4), the suspension was incubated for 2 h at room temperature. Total binding was 
determined by adding DMSO without test compound. Nonspecific binding was determined in 
the presence of 10 µM of unlabeled CP 55,940. Incubation was terminated by rapid filtration 
through GF/C glass fibre filtres presoaked for 0.5 h with 0.3% aq. polyethyleneimine solution, 
using a Brandel 96-channel cell harvester (Brandel, Gaithersburg, MD). Filters were washed 
  Materials and methods 22 
 
three times with ice-cold washing buffer (50 mM TRIS, 0.1% BSA, pH 7.4) and then dried 
for 1.5 h at 50 °C. Radioactivity on the filters was determined in a liquid scintillation counter 
(Topcount NXT, Packard/Perkin-Elmer) after 10 h of preincubation with 50 µl of scintillation 
cocktail (Multiscint 25, Perkin-Elmer). Data were obtained in three independent experiments, 
performed in duplicates. Data were analyzed using GraphPad Prism Version 4.02 (San Diego, 
CA, USA). For the calculation of Ki values the Cheng-Prusoff equation and a KD value of 2.4 
nM ([3H]CP 55,940 at CB1) and 0.7 nM ([3H]CP 55,940 at CB2) were used. 
 
3.6.6 Free fatty acid receptor (FFAR) 1 assay 
 
Free fatty acid receptor assay was done via measuring the concentration of calcium 
mobilization. To generate a cell line for calcium mobilization assays the cDNA sequence of 
GPR40 was inserted into the retroviral plasmid pLXSN. The retroviral transfection of 1321N1 
astrocytoma cells was performed as previously described. On the day before the assay the 
cells recombinantly expressing GPR40 were seeded into 96 well plates (black, clear bottom) 
at a density of 50000 cells per well. On the day of the assay the medium was exchanged for 
40 µl of a HBSS buffer solution containing 3 µM of the calcium dye Fluo-4-AM (Life 
Technology, Darmstadt, Germany) and 0.06% Pluronic F-127. After 60 min of incubation at 
rt in the dark the dye solution was exchanged for 190 µl of HBSS buffer in agonist assays. 
Using a FlexStation® 3 plate reader (Molecular Devices, Sunnyvale, CA) 10 µl of test 
compound (=agonist) solution were added to each well. The final DMSO concentration did 
not exceed 1%. Fluorescence was measured at 520 nm (excitation 485 nm) for 90 intervals of 
1.2 s each. All compounds were tested at a final concentration of 10 µM. Signals induced by 
the test compounds were normalized to the signals induced by 10 µM of TUG-424 in agonist 
assays. Three to four independent experiments were performed in duplicates. 
 
3.6.7 Cell viability test 
 
Cell viability was assessed using a fluorimetric detection of resorufin (CellTiter-Blue Cell 
Viability Assay, Promega). HEK293 cells were seeded at a density of 27,000 cells per well 
into black 96-well poly-D-lysine–coated plates with clear bottom. Three hours after seeding, 
cells were treated with 0.3% DMSO or compound dissolved in medium for 24 h. To detect 
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cell viability, CellTiter-Blue reagent was added and cells were incubated for 1 h at 37°C 
according to the manufacturer’s instructions. Fluorescence (excitation 560 nm, emission 590 
nm) was measured using a FlexStation 3 Benchtop Multimode Plate Reader and data were 
expressed as percentage of cell viability relative to DMSO control. (The cytotoxic anticancer 
drug etoposide was used as a positive control). Tests were performed from Nicole Merten, 
University of Bonn.  
 
3.6.8 Leukemic cell line assays 
 
Cell viability assessment was done with K562, Jurkat, Raji and U937 cells. Cells were 
incubated with different concentrations of stemphol during 8, 24, 48 and 72 h.  
Trypan blue exclusion assay (Biowhittaker, South Korea) was applied for cell viability. Mode 
of cell death was determined and quantified based on nuclear morphology and staining status 
after staining with Hoechst 33342 (Sigma-Aldrich, South Korea) and propidium iodide 
(Sigma-Aldrich, South Korea). To check the caspase-dependency, 50µM zVAD-FMK 
(Calbiochem, South Korea) was pretreated to stemphol and cells were observed by 
fluorescence microscopy (Nikon eclipse Ti-U, Nikon Instruments Korea, South Korea). 
Data were normalized to the control and reported as percentage of viable active cells. 
 
 
3.6.9 ROS measurements 
 
After treating stemphol for indicated time period, stained the cells with 10µM of 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) (LifeTechnologies) for 20min, 37°C in the 
dark. The fluorescence intensity was assessed using by FACSCalibur and H2O2 was used as a 
control positive. 
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3.7 Chemicals and solvents 
Acetic acid    Merck (Darmstadt, Germany) 
Acetone-d6 99.8%    Deutero GmbH (Kastellaun, Germany) 
Acetonitrile    KMF (Lohmar, Germany) 
Acetonitrile Lichrosolv, LC-MS grade  Merck (Darmstadt, Germany) 
Agar-Agar    Fluka (Buchs, Switzerland) 
Ammonium acetate    Merck (Darmstadt, Germany) 
Ammonium hydroxide   Merck (Darmstadt, Germany) 
Benzyl penicillin    Fluka (Buchs, Switzerland) 
Biomalt extract     Villa Natura (Kirn, Germany) 
CaCl2 × 2 H2O    Merck (Darmstadt, Germany) 
Chloroform    Merck (Darmstadt, Germany) 
Chloroform-d1 99.8%   Deutero GmbH (Kastellaun, Germany) 
Dichloromethane    Sigma-Aldrich (Steinheim, Germany) 
Glucose     Merck (Darmstadt, Germany) 
HCl, 37%     Merck (Darmstadt, Germany) 
H2O Lichrosolv, LC-MS grade   Merck (Darmstadt, Germany) 
H2SO4     Merck (Darmstadt, Germany) 
Hexanes (mixture of isomers)   Sigma-Aldrich (Steinheim, Germany) 
Malt-extract    Roth (Karlsruhe, Germany) 
Methanol Lichrosolv, LC-MS grade  Merck (Darmstadt, Germany) 
Methanol-d4 99.8 % D   Deutero GmbH (Kastellaun, Germany) 
NaCl     Merck (Darmstadt, Germany) 
NaHCO3      Merck (Darmstadt, Germany) 
NaOH     Merck (Darmstadt, Germany) 
Na2SO4      Merck(Darmstadt, Germany) 
Penicillin/Streptomycin   Biomol GmbH (Hamburg, Germany) 
Tetrahydrofuran-d8    Deutero GmbH (Kastellaun, Germany) 
Triethylamine    Sigma-Aldrich (Steinheim, Germany) 
Yeast extract    Roth (Karlsruhe, Germany) 
Vanillin     Merck (Darmstadt, Germany)  
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All other chemicals were supplied by Merck (Germany), Fluka (Switzerland), Roth 
(Germany) and Sigma-Aldrich (Germany). All other solvents were research grade and 
supplied by Infracor or BASF. Acetone, CHCl3, CH2Cl2, EtOAc, MeOH and PE were distilled 
prior to use. Water for HPLC was de-ionized using a Millipore (milli-Q® academic) system. 
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4.         Results 
4.1 Novel fungal metabolite stemphyloxin III (1) 
 
4.1.1 Cultivation and extraction of stemphyloxin III (1) 
Fungal biomass and media were homogenized and extracted with EtOAc to yield 1.7 g of the 
extract. The material was fractionated employing NP-VLC (0.063-0.200 mm, Merck) using 
stepwise elution from petrolether to EtOAc to MeOH to afford 10 fractions. Of these, fraction 
2 was further separated via another NP VLC (0.040-0.063 mm, Merck), whereas the 
subfraction 2.15 gained 25 mg (Figure 8). Further purification was achieved by RP-HPLC to 
afford 7.5 mg of Fraction 2.15.4.  Stemphyloxin III (1) was finally isolated via two more 
HPLC fractionations to yield 0.7 mg (Figure 7).  
 
Figure 7: Structure of stemphyloxin III (1) 
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4.1.2 Isolation of stemphyloxin III (1) 
 
Figure 8: Isolation scheme of stemphyloxin III (1) 
Fraction 2
347 mg
Fraction 3
312 mg
Fraction 4
40 mg
Fraction 5
43 mg
Fraction 6
27 mg
Fraction 7
160 mg
Fraction 8
70 mg
Fraction 9
16 mg
Fraction 10
11 mg
Fraction 1
68 mg
crude extract
ca. 1.7 g
Stemphylium
globuliferum
10 L PDA+SoAc-media
Fraction 2.15
25 mg
Fraction
2.15.1
7.2 mg
Fraction
2.15.2
1.1 mg
Fraction
2.15.3
1.0 mg
Fraction
2.15.4
7.5 mg
Fraction
2.15.4.2
3.5 mg
Fraction
2.15.4.1
2.4 mg
Fraction
2.15.4.2.1
1.0 mg
Fraction
2.15.4.2.2
0.7 mg (1)
NP VLC stepwise gradient:
PE-DCM-EtOAc-MeOH
Extraction 3x 
EtOAc
NP VLC stepwise gradient:
DCM-EtOAc-MeOH
HPLC RP Eurospher C18, 
MeOH/H2O (80/20)
1,4 ml/min
HPLC RP Kinetex C18, 
MeOH/H2O (52/48)
1ml/min
HPLC RP Nucleodur
100-5 C18, ACN/H2O 
(40/60 – 100/0)
1 ml/min
 
  Results 28 
 
4.1.3 Structure elucidation of stemphyloxin III (1) 
 
Compound 1 was isolated from the endophytic fungus St. globuliferum (OS1Test1-2) and its 
structure was elucidated via intensive analysis of spectroscopic data including one and two 
dimensional NMR data. The IR spectrum contained absorptions at 1710 cm-1, 1670cm-1 and 
1580 cm-1 pointing towards carbonyl and carboxyl functions, respectively. The molecular 
formula was deduced from the results of a HR-ESI-MS measurement, whereby m/z = 
435.2686 [M + H]+ corresponded to C25H38O6 (calcd: 435.2702 [M + H]+). The 13C-NMR and 
DEPT-135 spectra showed 25 resonances for five methyl groups and a methoxy group, four 
methylene and eleven methine groups, as well as four quarternary carbon atoms (Table 1). 
Functional groups within 1 were deduced from 13C-NMR signals for a ketone at δ 205.5 (C-
9), two carboxyl carbons resonating at δ 177.9 (C-23) and 174.5 (C-20), and additionally 
resonances for four olefinic carbons at δ 165.4 (C-11), δ 126.7 (C-4), δ 125.4 (C-3) and δ 
103.1 (C-10). 
Analysis of the 1H-1H COSY spectrum allowed to delineate partial structures A-D (Figure 9). 
Thus, COSY correlations of H-2 through to H-8a, including the methyl group resonances 
CH3-18 and CH3-19 gave the first partial structure A (Figure 9).   
1H-1H COSY correlations of the 1H-NMR resonance signals for H-10 and H-11 and a 
coupling constant of J = 12.3 Hz, as well as a NOESY correlation between H-10 and H-11 
indicated a cis configured double bond (B in Figure 9). The third 1H-1H spin-system (C in 
Figure 9) is a four membered alkyl chain based on correlations between H-14, H3-17, H2-15 
and H3-16 and represents a secondary-butyl-moiety. Moiety D (Figure 9) was elucidated via a 
COSY correlation between H2-21 and H2-22.  
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Table 1: NMR spectroscopic data (600 MHz) of compound 1 in MeOH-d4 
Pos. δH in ppm, mult., J (Hz) δC in ppm 1H-1H COSY-Correlations HMBC-Correlations NOE-Correlations 
1  53.7, C    
2 1.94, m 53.5, CH H-3  H-3, H3-13, H-14, H3-17 
3 5.72, m 125.4, CH H-2, H-4  H-2, H3-17 
4 5.69, m 126.7, CH H-3, H-4a  H-4a, H-5 
4a 1.99, br t (10.0) 45.0, CH H-4, H-5, H-8a  H-4, H-6, H-8, H3-13, H2-21, H2-
22 
5 4.53, t (10.0) 82.2, CH H-4a, H-6 C-20 H-4, H-7b, H-8a, H3-18 
6 1.76, m 39.8, CH H-5, H3-18  H-4a, H-8, H3-18 
7a 
 
a:1.75, m 
 44.7, CH2 
 
H-7b 
 
C-6 
 
H-7b, H-8, H3-18, H3-19 
b: 1.13, q (12.5) H-6, H-7a, H-8 C-6 H-5, H-7a, H-8a, H3-19 
8 1.49, m 38.0, CH H-7b, H-8a, H3-19  H-4a, H-6, H3-19 
8a 2.07, m 45.0, CH H-4a, H-8  H-5, H-7b, H3-19 
9  205.5, C    
10 6.18, d (12.3) 103.1, CH H-11  H-11, H3-13 
11 7.61, d (12.3) 165.4, CH H-10 C-9, C-12 H-10, H3-12 
12 3.80, s 58.6, CH3  C-11  
13 1.29, s 20.0, CH3  C-1, C-2, C-8a, C-9 H-2, H-4a, H-10, H-8 
14 1.38, m 37.9, CH H-15b, H3-17  H-2 
15 
 
a: 1.58, m 
 26.2, CH2 
 
H-15b, H3-16 
 
C-16 
 
H-15b, H3-16 
b:  0.82, m H-15a, H3-16 C-17 H-15a, H3-17 
16 0.81, t (5.0) 12.9, CH3 H-15a C-14, C-15 H-15a 
17 0.94, d (7.0) 19.7, CH3 H-14 C-2, C-14, C-15 H-2, H-14 
18 0.93, d (6.2) 18.9, CH3 H-6 C-5, C-6, C-7 H-5, H-6 
19 0.73, d (7.0) 22.5, CH3 H-8 C-7, C-8, C-8a H-7b, H-8, H-8a 
20  174.5, C    
21 2.60, m 31.7, CH2 H2-22 C-20, C-22, C-23  
22 2.71, m 31.2, CH2 H2-21 C-20, C-21, C-23  
23  177.9, C    
 
The analysis of the HMBC spectrum led to the conclusion that the carboxyl function C-20 is 
attached to C-21 and the carboxylic carbon C-23 to C-22, as crosspeaks between H2-21 to C-
20, C-22 and C-23, as well as H2-22 to C-20, C-21 and C-23 were detected (see Figure 10). 
Altogether this resulted in a succinyl-moiety. Further analysis of the HMBC spectra led to an 
extension of partial structure A, since crosspeaks between the resonances for the methyl group 
H3-13 and C-2, as well as C-1, C-8a and C-9 were observed. The latter carbon is part of 
residue B (Figure 9), due to a HMBC correlation from H-11 to C-9. Thus led to the 
conclusion that compound 1 has a decaline core structure, where C-1 connects the above 
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mentioned substructures A and B. The HMBC correlations between H3-17 to C-14, C-15 and 
C-2 showed the connection of the butyl residue (C in figure 9) to the decaline structure.  
A HMBC correlation arising from the resonance of H-11 to CH3-12 clarified the position of 
the methoxy group and identified the side chain at C-1 as a methoxylated β-hydroxyenone. 
Finally, the succinyl moiety had to be connected via an ester bond to C-5 due to an HMBC 
correlation of H-5 to C-20. 
 
Figure 9: Selected partial structures of  
stemphyloxin III (1) deduced from 1H-1H 
COSY correlations marked as bold lines 
    
Figure 10:   Selected HMBC correlations of            
stemphyloxin III (1) marked as red arrows 
      
 
  
         
 
The relative configuration was deduced from data in a NOESY spectrum. Correlations 
between H-2 and H3-13, H3-13 to H-2 and H-4a and furthermore H-4a to H-6 and H-8 showed 
that all these protons are on the same side of the molecule, i.e. α. In addition, NOE 
correlations of H-8a to H-5 and H-7b indicated these protons to be β positioned. The position 
of H-4a is approved by 1H coupling constant of J4a – 5 = 10 Hz, which showed that the dihedral 
angle between these protons is 180° (Figure 11). Therefore, the connection of the decaline 
ring is trans (H-4a to H-8a, Figure 12), which corresponds with literature data of coincenal D 
(Wang et al., 2013). The coupling constant of J7a - 7b = 12.5 Hz pointed towards a geminal 
coupling towards H-7a and H-7b. Additionally, the vicinal coupling constants of J7b – 6 = 12.5 
Hz and J7b – 8= 12.5 Hz showed that H-7b is axial to H-6 and H-8.  
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The NOE coupling of H-2 and H3-13 pointed towards an equatorial position of the secondary 
butyl group, which is connected to C-2, and the β-hydroxyenone moiety which is connected to 
C-1, respectively. Furthermore the coupling of H-6 and H-8 led to the conclusion, that H3-18 
and H3-19 are in equatorial position connected to C-6 and C-8, respectively (Figure 12.  
 
Finally the relative configuration of stemphyloxin III is shown in Figure 7. 
 
Figure 11: 3D model of stemphyloxin III (1) determined by conformation search (Boltzmann 
jump) using CVFF1.01 (see 3.5.7) 
 
 
Figure 12: Key NOE correlations of compound 1 marked as red arrows 
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The structure of compound 1 has similarities to three known natural products, i.e. 
stemphyloxin I (Figure 14), probetaenone I (Figure 16) and coicenal D derivative (Figure 15) 
(Sakamura et al., 1988; Liu et al., 2013; Barash et al., 1984). The 13C-NMR resonances of the 
decaline core structure and the secondary butyl moiety of 1 are mostly alike to those of 
probetaenone I (Table 2) except for C-5, where compound 1 has the linkage to the succinyl 
unit (Sakamura et al., 1988). In turn, the 13C-NMR resonances of the succinyl residue had 
similarities to a coincenal D derivative, where also the succinyl unit is linked to the decaline 
core structure (Liu et al., 2013). Furthermore, the 13C-NMR signals at δ 205.5 (C-9), δ 165.4 
(C-11) and δ 103.1 (C-10) are similar to those reported for stemphyloxin I, which also has an 
enone group attached to the decaline core structure (Barash et al., 1984).  
 
Based on the intensive study of the above mentioned spectroscopic data the unambiguous 
configuration of compound 1 is shown in Figure 7, and the compound is named stemphyloxin 
III.  
 
4.1.4 Antimicrobial activity of stemphyloxin III (1) 
 
Stemphyloxin III (1) was tested against a broad spectrum of microorganisms, that is, the 
Gram-positive bacteria Staphylococcus aureus 133, Bacillus subtilis 168, Micrococcus luteus 
4698, Arthrobacter crystallopoites DSM 20117, the Gram-negative bacteria Escherichia coli 
I-11276b, Klebsiella pneumoniae sp. ozeanae I-10910 and the fungus Candida albicans I-
11301. The compound revealed a moderate antibiotic activity against Arthrobacter 
crystallopoietes with an inhibition of 7 mm and against Micrococcus luteus with an inhibition 
of 5 mm (3µg/assay). The test was performed by Michaele Josten from the group of Prof. 
Tanja Schneider, Institute of Pharmaceutical Microbiology, University of Bonn.  
 
 
 
 
 
 
 
 
 Results   
 
33
 
Figure 13: Stemphyloxin III (1) 
 
Figure 14: Stemphyloxin I (Barash et al., 1984) 
 
 
Figure 15: Coicenal D derivative (Liu et al., 
2013) 
 
Figure 16: Probetaenone I (Sakamura et al, 
1988) 
 
 
 
 
Stemphyloxin III (1) was obtained as white powder (0.07 mg/L). [α]20D = - 15.71 (c = 0.07, 
EtOH); UV (EtOH) λmax (log ε): 258 nm (3.96); IR vmax 2860, 1710, 1650, 1580, 1250, 1180 
cm-1 (see Appendix); 1H-and 13-C data see Table 1; HR-ESI-MS 435.2686 [M + H]+ for 
C25H38O6  (calcd: 435.2702 [M + H]+). 
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Table 2: Compared 13C NMR Spectroscopic Data of compound 1, probetaenone I, stemphyloxin 
I and coicenal D derivative 
Pos. 
δC in ppm 
compound 1 a 
δC in ppm 
probetaenone I1, b 
δC in ppm 
stemphyloxin I2, c 
δC in ppm 
coicenal D derivative3, c 
 
1 53.7 53.9 49.9 50.4 
2 53.5, CH 57.1 45.0 50.0 
3 125.4, CH 130.8 75.9 132.4 
4 126.7, CH 127.2 216.5 125.5 
4a 45.0, CH 42.6 55.0 84.9 
5 82.2, CH 42.4 41.6 78.5 
6 39.8, CH 34.0 68.7 34.2 
7 44.7, CH2 46.6 47.6 43.3 
8 38.0, CH 38.0 31.1 29.7 
8a 45.0, CH 44.4 40.5 59.9 
9 205.5, C 215.0 207.2 182.5 
10 103.1, CH 41.4 101.7 102.8 
11 165.4, CH 58.0 172.2 190.2 
12 58.6, CH3    
13 20.0, CH3 17.8  21.6 
14 37.9, CH 34.8 43.0 33.2 
15 26.2, CH2 27.0 19.7 26.5 
16 12.9, CH3 13.3  12.5 
17 19.7, CH3 21.7 66.1 21.0 
18 18.9, CH3 22.3  17.4 
19 22.5, CH3 23.6  19.5 
20 174.5, C   171.8 
21 31.7, CH2   29.2 
22 31.2, CH2   28.7 
23 177.9, C   174.9 
a in MeOD, b in C6D6, c in CDCl3;  1 Sakamura et al; J.Chem.Soc., Chem. Commun., 1988; 600-602 
 
2
 Barash et al.; Phytochemistry, 1984, Vol.23, No. 10, 2193-2198 
3 Liu et al.; Organic Letters, 2013, Vol. 15, 3982-3985 
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4.2 Novel fungal metabolite stemphylofuran (2) 
 
4.2.1 Cultivation and extraction of stemphylofuran (2) 
Stemphylofuran (2) was isolated from the endophytic fungus St. globuliferum. After 
homogenization and extraction of the fungal biomass and media with EtOAc 3.0 g of crude 
extract were obtained (Fig. 18). The material was fractionated employing NP-VLC (0.063-
0.200 mm, Merck) using stepwise elution from petrolether to EtOAc to MeOH to afford 11 
fractions. Of these, fraction 5.8 was further separated via a medium pressure liquid 
chromatography of which the subfraction 5.8.5 gained 6.5 mg. Stemphylofuran (2) was finally 
isolated via an RP-HPLC fractionation to yield 1.2 mg (Figure 17). 
 
Figure 17: Structure of stemphylofuran (2) 
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4.2.2 Isolation of stemphylofuran (2) 
 
Figure 18: Isolation scheme of stemphylofuran (2) 
Fraction 5.2
8 mg
Fraction 5.3
359 mg
Fraction 5.4
91 mg
Fraction 5.5
32 mg
Fraction 5.6
373 mg
Fraction 5.7
505 mg
Fraction 5.8
147 mg
Fraction 5.9
69 mg
Fraction 5.10
323 mg
Fraction 5.1
12 mg
crude extract
ca. 3.0 g
Stemphylium
globuliferum
10 L PDA-medium
Fraction
5.8.5.1
0.7 mg
Fraction
5.8.5.2
1.1 mg
Fraction 5.8.5
6.5 mg
NP VLC stepwise gradient:
PE-DCM-EtOAc-MeOH
Extraction 3x 
EtOAc
Fraction 5.11
204 mg
Fraction 5.8.5.3
1.6 mg
Compound 2
MPLC Grace Reveleris, 
C18 40µm 12g
20 ml/min
RP HPLC , Nucleoshell
C18 Macherey-Nagel, 
MeOH/H2O (25/75) 
1 ml/min
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4.2.3 Results and discussion 
The molecular formula was deduced from the results of a HRESIMS measurement, i.e. m/z = 
263.0886 [M + H]+ corresponded to a molecular formula of C14H14O5 (calcd: 263.0875 [M + 
H]+). The calculated number of double bond equivalents was 8. The UV spectrum showed a 
maximum at 350 nm, clearly evidencing an extended chromophore. The IR spectrum of 2 
contained absorptions at 1650 cm-1 and 3300 cm-1 pointing towards carbonyl and hydroxyl 
functionial groups, respectively. The structure of stemphylofuran (2) was elucidated via 
intensive analysis of one and two dimensional NMR data. The 13C-NMR and DEPT-135 
spectra showed 14 resonances for two methyl groups, one methylene and four methine 
groups, as well as seven quaternary carbon atoms. Functional groups within the molecule 
could be deduced from 13C-NMR signal, for two ketones at δ 199.5 (C-1) and δ 199.3 (C-2), 
respectively (Table 3). 
 
 
Table 3: NMR spectroscopic data (600 MHz) of compound 2 in MeOH-d4 
Pos. 
δH, in ppm, mult., 
J (Hz) 
δC in ppm 
1H-1H COSY-
Correlations 
HMBC-Correlations NOE-Correlations 
1 
 
199.5, C 
   
2 
 
199.3, C 
   
3 
 
161.1, C 
   
4 
 
156.7, C 
   
5 
 
151.4, C 
   
6 
 
129.3, C 
   
7 7.27, brs 128.5, CH H3-8, H-9, H-10 
C-1, C-4, C-5, C-6, C-9, C-
11 
H3-14 
8 
 
6.13, s 124.5, CH 
H-14, H-7 
 
C-6, C-11, C-14 
 
H3-14 
 
9 7.57, d (3.5) 122.1, CH H-10, H2-12, H-7 C-3, C-5,  C-7, C-10 H-10 
10 6.56, d (3.5) 111.9, CH H-9, H2-12 C-9, C-5, C-3 H-9, H2-12 
11  85.7, C    
12 4.61, s 57.6, CH2 H-10 C-10, C-3 H-10 
13 1.55, s 26.6, CH3  C-11, C-2  
14 2.34, s 20.3, CH3 H-8 C-8, C-6, C-4, H-7, H-8 
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Analysis of the 1H-1H COSY spectrum allowed to delineate a clear spin system involving H-
10 and H-9. Further long range H-coupling established a range of conjugated double bonds 
from H-9 to H-7 and H-7 to H-8, as well as an additional coupling between H-9 and H2-12, 
and H-10 and H2-12 (Figure 19). 
 
Figure 19: 1H-1H COSY correlations of stemphylofuran (2)  
 
 
 
The analysis of the 1H-13C-HMBC spectrum showed correlations between H-10 and C-9, C-5 
and C-3, and between H-9 and C-3, C-5 and C-10. These data together with 13C-NMR 
chemical shifts of carbons C-3 and C-5 indicated the presence of a furan ring (Figure 20). The 
methylene group H2-12 is attached to the C-3 of this furan ring, because of a HMBC 
correlation between H2-12 and C-3. 
H-8 showed correlations to C-6, C-11 and C-14, and H3-14 correlations with C-4, C-6 and C-
8. This led to the conclusion that CH3-14 is connected to C-6, whereas C-6 is connected to C-
4 and C-8 respectively. Correlations of H-7 to C-1, C-4, C-6 finally indicated the presence of 
a cyclopentenone ring and the connection between the furan moiety and the cyclopentenone 
moiety via C-7. H3-13 has correlations with carbonyl C-2 and C-11, and revealed that an 
acetyl group is attached to C-11.  
Taking the molecular formula into account, two hydroxyl groups still have to be connected. 
The first one is attached to C-11, the second one to C-12, to gain the hydroxymethyl group on 
the furan ring. This is supported by the 13C-NMR chemical shifts of these carbons.  
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Figure 20: Selected HMBC correlations of stemphylofuran (2) marked as red arrows 
 
 
The final structure of stemphylofuran was established by analyzing a NOE spectrum. 
Correlations of both H-7 and H-8 to H3-14 led to the conclusion that all protons are on the 
same side (Figure 21) and thus established the configuration of the double bond ∆4.7 to be Z. 
The configuration at C-11 could not be resolved. The CD experiment lead to a positive, but 
very weak cotton effect at 382 nm.  
 
 
Figure 21: Key NOE correlations of compound 2 
 
 
Figure 22: Alternative structure of (2) 
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In part our spectroscopic data would also support the structure for 2, as shown in Figure 22. 
Thus was rejected, since H-9 has a HMBC correlation to C-7, but not to C-4, which indicated 
a five membered ring structure. The other fact is that there is a NOE correlation of H-7 to H3-
14, which is only possible if 2 is as descriped in Figure 21. With the six membered ring a 
NOE correlation between these protons H3-14 and H-7 is not possible because of sterical 
reasons. This led to the conclusion, that the metabolite has a five membered cyclopentenone 
ring.  
 
Based on the intensive study of the above mentioned spectroscopic data of compound 2, its 
structure is as shown as in Figure 7 and it is named stemphylofuran.  
 
 
Stemphylofuran (2) has similarities to phellinusfuran A (Figure 23), a furan derivative from 
Phellinus linteus (Min et al. 2006). The 13C-NMR resonances of the furan moiety as well as 
that of C-7, the linkages of both molecules are mostly alike (Table 2). Furthermore, NMR 
shifts of hydroxymethyl C-12 with is connected to the furan moiety are similar to the 
literature. C-4 of stemphylofuran resonating at δC 156.7 is downfield shifted compared to 
phenillusfuran A (δC 126.7). The structure of the investigated metabolite is a rare carbon 
skeleton, only found in the fungus Phellinus linteus so far.   
 
Figure 23: Phellinusfuran A (Min et al., 2006) 
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Table 4: Comparison of 13C NMR spectroscopic data of compound 2 and Phellinusfuran A 
Pos. 
δC, 
Compound 2 a 
δC, 
phellinusfuran A b 
1 199.5, C 196.8, C 
2 199.3, C  
3 161.1, C 160.6, C 
4 156.7, C 126.7, C 
5 151.4, C 149.3, C 
6 129.3, C 80.8, CH 
7 128.5, CH 121.4, CH 
8 124.5, CH  
9 122.1, CH 121.7, CH 
10 111.9, CH 110.3, CH 
11 85.7, C 99.1, CH 
12 57.6, CH2 56.0, CH2 
13 26.6, CH3  
14 20.3, CH3 74.4, CH 
a in MeOD; b in DMSO-d6, Min et al., Bioorg. & Med. Chem. Letters 16 (2006) 3255-3257 
 
 
Stemphylofuran (2) was obtained as yellow powder (0.12 mg/L). [α]20D = 0.04 (c = 0.1, 
EtOH); UV (EtOH) λmax (log ε): 350 nm (3.45); CD (MeOH): ∆ε 382= + 0.45; IR vmax= 3300, 
2850, 2380, 1650, 1410, 1190, 1110 cm-1 (see Appendix); 1H- and 13-C data see Table 3; HR-
ESI-MS 263.0886 [M + H]+ for C14H14O5  (calcd: 263.0875 [M + H]+). 
 
 
4.2.4 Antimicrobial activity of stemphylofuran (2) 
 
Stemphylofuran (2) was tested against a broad spectrum of microorganisms, that is, the Gram-
positive bacteria Staphylococcus aureus 133, Bacillus subtilis 168, Micrococcus luteus 4698, 
Arthrobacter crystallopoietes DSM 20117, the Gram-negative bacteria Escherichia coli I-
11276b, Klebsiella pneumoniae subsp. ozeanae I-10910 and the fungus Candida albicans I-
11301. The compound revealed a moderate antibiotic activity towards Arthrobacter 
crystallopoietes with an inhibition of 5 mm, and against Micrococcus luteus with an inhibition 
of 3 mm (3µg/assay). The test was performed by Michaele Josten from the group of Prof. 
Tanja Schneider, Institute of Pharmaceutical Microbiology, University of Bonn.  
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4.3 Fungal metabolite stemphol (3) 
 
4.3.1 Cultivation and extraction 
The fungus Stemphylium globuliferum was grown on Biomalt salt agar + 1% SoAcetate for 
40 days (room temperature and permanent light). Fungal biomass and media were 
homogenized and extracted three times with EtOAc to yield 1.7 g of the extract. The material 
was fractionated employing NP-VLC (0.063-0.200 mm, Merck) using stepwise elution from 
petroleum ether to EtOAc to MeOH to afford 10 fractions. Of these, fraction 2 was further 
separated via another NP VLC (0.040-0.063 mm, Merck), to gain 39 mg of subfraction 2.3 
(Table 6). Further purification was achieved by RP-HPLC to afford 15.2 mg of fraction 2.3.1, 
i.e. stemphol (3) (Figure 24).   
 
Figure 24: Isolation scheme of stemphol (3) 
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4.3.2 Isolation of fungal metabolite stemphol (3) 
Table 5: Isolation scheme of stemphol (3) 
Fraction 2
347 mg
Fraction 3
312 mg
Fraction 4
40 mg
Fraction 5
43 mg
Fraction 6
27 mg
Fraction 7
160 mg
Fraction 8
70 mg
Fraction 9
16 mg
Fraction 10
11 mg
Fraction 1
68 mg
crude extract
ca. 1.7 g
Stemphylium
globuliferum
10 L BMS-medium
Fraction 2.3
39 mg
NP VLC stepwise gradient:
PE-DCM-EtOAc-MeOH
Extraction 3x 
EtOAc
NP VLC stepwise
gradient:
DCM-EtOAc-MeOH
Fraction 2.3.1
15.2 mg (3)
HPLC RP Nucleodur
100-5 , 5 µm, C18
MeOH/H2O (90/10)
0.8 ml/min
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4.3.3 Results and discussion 
 
Structure elucidation of 3 was done via intensive analysis of one and two dimensional NMR 
spectra, as well as by mass spectrometric measurements. The molecular formula was deduced 
from a HR-ESI-MS measurement i.e. m/z = 237.1836 [M + H]+ corresponded to the molecular 
formula of C15H24O2, (calcd: 237.1854 [M + H]+). 
The 13C-NMR and DEPT-135 spectra revealed 14 resonances for two methyl, seven 
methylene and two methine groups, as well as four quarternary carbons (Table 6). The 1H-
NMR showed two prominent resonances at δ 6.89 (H-5) and δ 6.46 (H-6), that pointed to two 
aromatic protons.   
Analysis of the 1H-1H COSY spectrum allowed to delineate partial structures A and B. Thus, 
COSY correlations of H2-7 through to H3-14 gave evidence for partial structure A, 
correlations between H2-10, H-8a, H-12 and H3-13 for partial structure B (Figure 25). 
 
 
Figure 25: Selected partial structures of compound 3 deduced from 1H-1H COSY correlations 
marked as bold lines 
 
 
 
 
In this thesis, HMBC spectroscopic data were analyzed to identify the length of the alkyl 
chains on the resorcinol core structure. The analysis of the HMBC spectrum revealed that H-5 
has correlations to carbons C-2, C-4, C-6 and C-7 (Figure 26) and furthermore correlations of 
H-6 to carbons C-1, C-4, C-5 and C-7. Together with HMBC correlations of H2-7 to C-3, C-5 
and C-6 this led to the conclusion that carbons C-1 – C-6 form a phenyl ring with moiety A 
connected to carbon C-3. Furthermore, NOE correlations of H2-7 to H-5 and H-6 underline 
the assumption (Figure 27). A COSY correlation between H-5 and H-6 together with a 
coupling constant of 1.3 Hz indicated these two protons to be in meta position to each other. 
Fragment B had to be connected to C-4 due to HMBC correlations of H2-10 to C-1, C-2 and 
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C-4 (Figure 26). Based on the NMR data and the mass spectra the two remaining hydroxyl 
groups had to be attached to C-1 and C-2 respectively, which is confirmed by the downfield 
shift of these carbons in the 13C-NMR spectrum (Table 6).  
 
Figure 26: Selected HMBC correlations of compound 3 marked as arrows 
 
 
 
Figure 27: Key NOE correlations of compound 3 marked as arrows 
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Table 6: NMR spectroscopic data (300 MHz) of compound 3 in MeOH-d4 
Pos. 
δH in ppm, mult., J 
(Hz) 
δC in ppm 
1H-1H COSY-
Correlations 
HMBC-
Correlations 
NOE-Correlations 
1  156.9, C    
2  152.7, C    
3  142.0, C    
4  120.9, C    
5 6.89, d (1.3) 113.7, CH H-6, H2-7 
C-2, C-4, C-
6, C-7 
H2-7, H2-9 
6 6.46, d (1.3) 112.5, CH 
H-5, H2-7, 
H2-9 
C-1, C-4, C-
5, C-7 
H2-7, H2-9 
7 2.50, t (7.5) 36.7, CH2 
H2-9, H2-5, 
H-6 
C-3, C-5, C-
6, C-8b, C-
9, C-11 
H-5, H-6, 
H2-9, H2-8b 
8a 1.55, m 32.7, CH2 H2-10 C-10, C-13 
H2-10, H2-
12,  H3-13 
8b 1.36, m 32.7, CH2 H2-9 
C-7, C-9, C-
11, C-14 
H2-7, H3-14 
9 1.62, m 32.2, CH2 H2-7, H2-8b 
C-7, C-8b, 
C-11 
H-5, H-6, 
H2-7, H2-8b 
10 2.70 t (7.5) 24.6, CH2 
H2-8a, H2-5, 
H2-6 
C-1, C-2, C-
4, C-8a, C-
12 
H2-12, H2-
8a 
11 1.37, m 23.6, CH2 H3-14, H2-7 C-8b, C-14 H2-9 
12 1.38, m 24.0, CH2 
H2-8a, H3-
13 
C-8a, C-13 H3-13 
13 0.96, t (7.0) 14.5, CH3 
H2-12, H2-
8a 
C-12, C-8a H2-8a 
14 0.93, t (6.8) 14.4, CH3 H2-11 C-11, C-8b H2-8b 
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Table 7: 13C-NMR spectroscopic data of compound 3 compared to stemphol b 
Pos. δC, in ppm  
compound 3 a 
δC, in ppm  
compound 3 + TFA a 
δC, in ppm 
stemphol b 
 1 156.9, C 156.9, C 154.2 
2 152.8, C 152.7, C 154.2 
3 142.0, C 142.1, C 142.1 
4 120.9, C 114.5, C 112.4 
5 113.7, CH 107.7, CH 108.0 
6 112.6, CH 107.7, CH 108.0 
7  36.7, CH2  36.7, CH2 35.1 
8a 32.7, CH2 32.7, CH2 31.4 
8b 32.7, CH2 32.7, CH2 31.4 
9 32.1, CH2 32.2, CH2 30.7 
10 24.6, CH2 23.9, CH2 22.8 
11 24.0, CH2 23.7, CH2 22.8 
12  23.6, CH3  23.6, CH3 22.5 
13  14.5, CH3  14.5, CH3 14.0 
14 14.4, CH3 14.4, CH3 14.0 
a in MeOD (300MHz); b in CDCl3, Marumo, S., Argic. Biol. Chem., 49 (5), 1985, 1521-1522, assignment of the respective carbons to their 
13C-NMR resonances was done according to the best Literature for compound 3 
 
According to literature, compound 3 had similarities to those of the known metabolite 
stemphol (Marumo et al. 1985) except for two proton signals at 6.46 ppm and 6.89 ppm for 
H-5 and H-6, respectively of compound 3 instead of a 1H-NMR signal at 6.2 ppm for H-2 of 
stemphol (Figure 29 and App. F1). This phenomenon can be explained by the phenol 
phenolate reaction. Phenol has higher acidities, e.g. compared to alcohols, due to the aromatic 
ring coupling and the possibility of a hydrogen ion loss. This proton loss correlates with the 
building and mesomeric stabilization of the gained phenolat-ion. The negative charge on 
oxygen is delocalized on to the ortho and para carbon atoms (Figure 28). After addition of 
TFA to compound 3 the protonated phenolicform was gained which is underlined by the fact 
that the 1H-NMR spectra showed a signal at 6.2 ppm for the magnetically equivalent protons 
H-5 and H-6 (Figure 29), similar as reported in the literature for stemphol (Marumo et al. 
1985).  
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Figure 28: Phenol phenolate reaction based on mesomeric stabilization of the negative charge of 
the phenolate ion 
 
 
Figure 29: Phenolate (marked in red) compared to phenolate with added TFA (blue) of (3) and 
their 1H-NMR (300 MHz) shifts between 6.13 ppm, 6.46 ppm and 6.89 ppm, respectively 
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MS fragmentation also supported the structure of 3. Thus, fragments at m/z = 166 and m/z = 
180 in the LC-MS (see 3.5.2) spectrum can be explained by the cleavage of the two alkyl 
groups from the phenol core structure, as well as β–cleavage and mesomeric stabilization at 
the C-3 position (Figure 30) according to literature (Occolowitz 1964). 
 
Taking together the above mentioned results of spectroscopic measurements, LC-MS 
measurements and MS fragmentation of the literature reports (Table 7) it was shown that 3 is 
the deprotonated form of 2-butenyl,-5-pentenyl-resorcin and thus, stemphol (3) as seen in 
Figure 24.  
 
 
Stemphol: C15H24O2 m/z = 237.1836 [M + H]+; white needles (1.52 mg/L); UV λmax: 205nm 
(see Appendix); 1H-NMR (MeOD, 300 MHz) δ 6.13 (2H, s), 2.54 (2H, t, J = 8.0 Hz), 2.39 
(2H, t, J = 8.0), 1.28-1.61 (10H, m), 0.93 (3H, t, J = 7.2), 0.91 (3H, t, J = 6.9); 13C-NMR 
(MeOD, 75 MHz) δ 157.0, 142.1, 114.5, 107.6, 36.7, 32.7, 32.6, 32.2, 23.9, 23.7, 23.6, 14.5, 
14.4 (corresponding to Marumo et al. 1985). 
 
Figure 30: MS fragmentation, alkyl cleavage of compound 3, pos.Mode LC-MS measurement 
 
 
 
 
 
  Results 50 
 
4.3.4 Antimicrobial activity of stemphol (3) 
 
Stemphol (3) was evaluated for its antimicrobial potential by two different agar diffusion 
assays and a microtiter plate assay for further determination of the MIC-value (see 3.6.1 and 
3.6.2) as shown in Table 8 and 9.  
 
 
Table 8: Agar diffusion assay of stemphol (3) in the group of Prof. König (see 3.6.1)  
Inhibition zones against test organisms [mm] 
Compound 
Escherichia 
coli 
Bacillus 
megaterium 
Microbotryum 
violaceum 
Eurotium 
rubrum 
Mycothypha 
microspora 
stemphol (3) - 4 3 - - 
sample concentration: 1mg/ml (at 50 µg/disk) 
 
 
Stemphol (3) showed antimicrobial activity against a range of microorganisms (Table 8 and 
9). The activity against Bacillus megaterium and Staphylococcus aureus was originally 
reported by Achenbach et al. 1979 and could be confirmed with an inhibition zone of 4 mm 
(Table 8). Furthermore, an inhibition of Microbotryum violaceum of 3 mm revealed the 
fungal inhibition according to literature (Achenbach et al. 1979). However, stemphol (3) was 
tested against other Gram-positive and Gram-negative bacteria as well as against Candida 
albicans, but showed no inhibition.   
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Table 9: Agar diffusion assay in the group of Prof. Sahl (and microtiter plates assay for MIC) 
values of stemphol (3) against certain microorganisms, shown are the inhibition zones [mm] as 
well as the minimal inhibition concentration [µg/ml] 
inhibition zones and MIC against test organisms 
Test organism stemphol (3) 
Strain No. 
Inhibition 
zone [mm] 
MIC 
[µg/ml] 
Staphylococcus aureus (MSSA) I-11574 4 n.t. 
Staphylococcus aureus (MRSA) LT-1334 3 4 
Staphylococcus aureus (MRSA) LT-1338 3 n.t. 
Staphylococcus aureus 133 4 4 
Staphylococcus simulans 22 4 4 
Bacillus subtilis 168 3  
Listeria welshimeri DSM 20650 4  
Mycobacterium smegmatis ATCC 70084 3  
Candida albicans I-11301 4 4 
Candida albicans I-11134 3 n.t. 
Arthrobacter crystallopoietes DSM 20117 4  
Enterococcus faecium I-10910 3 16 
Klebsiella pneumoniae sp. ozeanae I-11054 4 64 
Citrobacter freundii I-11090 2*  
Escherichia coli I-11276b 2*  
Escherichia coli O-19592 2*  
Stenotropomonas maltophilia O-16451 2*  
Stenotropomonas maltophilia I-10717 2*  
Pseudomonas aeruginosa I-10968 2*  
* Some colonies remaining, no clear inhibition, sample concentration: 1mg/ml (at 3 µg/disk), assay was done by Michaele Josten in the 
group of Prof. Sahl, University of Bonn; n.t.: not determined 
 
 
Stemphol (3) showed good activity against the Gram-positive bacteria St. aureus, methicillin-
resistant St.aureus and St. simulans with an MIC value of 4 µg/ml as well as against C. 
albicans with an MIC value of 4 µg/ml, which makes stemphol (3) to a considerable drug 
candidate towards these pathogens (Table 9). Furthermore, stemphol (3) was sensitive 
  Results 52 
 
towards E. faecium and K. pneumoniae subsp. ozeanae, with MIC values of 16 µg/ml and 64 
µg/ml, respectively (Table 9). There is also a weak activity towards certain Gram-negative 
bacteria, e.g. Stenotropomonas maltophilia or E. coli with an inhibition zone of 2 mm 
including some single remaining colonies. These pathogens play a leading role in nosocomial 
infections because of their resistance to the available antimicrobial options.  
 
 
4.3.5 Antiparasitic activity 
 
Protozoan parasites that are infectious to humans represent a significant threat to health. 
Malaria, a vector-borne disease caused by protozoan parasites of the genus Plasmodium e.g. 
P. falciparum, resulted in 214 million infections and claims 438.000 deaths every year (World 
Malaria Report 2015). 
Infections with Trypanosoma cause various diseases e.g. sleeping sickness caused by T. 
brucei and Chagas disease, caused by T. cruzi. Chagas disease mainly affects the poor in 
remote areas and is endemic in rural Latin America, where an estimated 18 million people are 
infected with the causative parasite that is transmitted by insects (Lancet 2009).  
Leishmania ssp. are parasites that cause leishmaniasis, a disease with 12 million infected 
people and one of the world´s most neglected diseases until few years ago (Srivastava et al. 
2016). Leishmaniasis is divided in three forms: cutaneous, mucocutaneous and viscerial 
leishmaniasis. They are transmitted via sandflies and during their life cycle stage in 
mammalian hosts, Leishmania ssp. are housed within phagolysosomes of macrophages 
(McGwire and Satoskar 2014).   
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Table 10: In vitro antiparasitic activity of stemphol (3) against seceral parasites and cytotoxic 
activity towards myoblast cell line 
 IC50 values test organism/cell line [µg/ml] 
pos. control T. b. rhod. T. cruzi L. donovani P. falciparum L6-cells 
Melarsoprol 0.002     
Benznidazole  0.465    
Miltefosine   0.074   
Chloroquine    0.004  
Podophyllotoxin     0.009 
Stemphol (3) 0.18 2.45 0.30 3.33 4.45 
T.b. rhod.: Trypanosoma brucei rhodesiense; T. cruzi: Trypanosoma cruzi; L.donovani: Leishmania donovani; P.falciparum: Plasmodium 
falciparum; L6-cells: rat skeletal myoblasts cells, assay was done in the workgroup of Dr. Kaiser, Swiss Tropical and Public Health Institute, 
Basel (see 3.6.3) 
 
Stemphol (3) revealed an antiparasitic activity towards Trypanosoma brucei subsp. 
rhodesiense and Leishmania donovani with an IC50 value of 0.18 µg/ml and IC50 0.30 µg/ml 
but also showed pronounced cytotoxicity towards the control cell cline, regarding the limited 
selectivity index of  25 and 15, respectively, making them problematic for further 
pharmaceutical drug development (Table 10). T. cruzi with an IC50 value of 2.45 µg/ml and P. 
falciparum with an IC50 value of 3.33 µg/ml are not selective compared to L6-cells (control). 
Another approach would be the derivatization of stemphol to reduce the cytotoxicity. All 
assays were done in the group of Dr. Kaiser, Swiss Tropical and Public Health Institute, 
Basel, Switzerland (see 3.6.3).  
 
 
 
4.3.6 Radioligand binding studies at CB1 / CB2 receptors 
 
Cannabinoid receptors (CB1 and CB2) belong to the family of G-protein coupled receptors 
and are part of the endocannabinoid system, which are involved in the regulation of various 
processes in the human body. They are located in the cell membrane and regulate via Gi 
coupling the inhibition of adenylate cyclase, which forms cyclic adenosine monophosphate 
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(cAMP), a second messenger involved in signal transduction. Their activation results in 
reduced intracellular cAMP levels (Matsuda et al. 1990).    
CB1 receptors are mainly present in the central nervous system and they affect a variety of 
physiological responses including analgesia, psychoactive effects, e.g. euphoria, and 
stimulation of appetite. CB2 is expressed in cells and organs of the immune system and its 
activation results in anti-inflammatory and analgesic effects (Racz et al. 2008; Pacher et al. 
2006). The most prominent target for the cannabinoid receptor is ∆9-tetrahydrocannabinol 
(∆9-THC), a secondary metabolite produced by the plant Cannabis sativa.  
In the here employed competition binding assay, the CB agonist radioligand [3H](−)-cis-3-[2-
hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP 55,940) 
was used. Nonspecific binding was determined in the presence of 10 µM of unlabeled CP 55, 
940 (see 3.6.5). Here, the Ki values determined a dissociation constant, which measures the 
affinity between a ligand (e.g. stemphol) and a protein (e.g. the CB receptor). Such ligand-
protein affinities are influenced by non-covalent intermolecular interactions between the two 
molecules such as electrostatic interactions, hydrogen bonding and van der Waals forces. 
Here, the Ki value corresponds to the concentration of ligand (e.g. stemphol) at which the 
binding site on the protein (e.g. CB receptor) is half occupied (Table 11).  
 
Table 11: Radioligand binding assay with stemphol (3) and other metabolites at human CB1 and 
CB2 receptors heterologous expressed in CHO cells 
  
 
Radioligand binding 
Compound  
 
hCB1 hCB2 
  
 
Ki (µM) 
(%) inhibition of specific 
binding 
Ki (µM) 
(%) inhibition of specific 
binding 
stemphol (3) 
 
 
6.65 ± 1.61 2.92 ± 0.27 
4-butyl-3,5-dihydroxy-benzoic 
acid (4)   
>10 (11%) >10 (9%) 
infectopyrone (5) 
 
 
>10 (7%) >10 (8%) 
assay performed by Dr. Clara Schoeder, group of Prof. Müller, University of Bonn 
 
 
In the radioligand binding assay stemphol (3) showed an affinity towards CB1 and CB2 
receptor at 6.65 µM for CB1 and 2.92 µM for CB2, respectively. Further isolated metabolites 
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4-butyl-3,5-dihydroxy-benzoic acid (4) and Infectopyrone (5) had no effect. The results in the 
lower micromolar range for stemphol (3) showed that stemphol had weak affinity towards the 
CB1 and CB2 receptors compared to the lower nanomolar range of the positive control CP  
55,940 of 2.4 nM at CB1 and 0.7 nM at CB2 receptor, respectively (see 3.6.5). This may be 
explained by the alkyl chains of stemphol, connected with the phenol core structure, which is 
similar to a partial structure of the naturally agonist ∆9-THC as well as the synthetic 
cannabinoid CP 55,940 (Figure 31). 
 
 
Figure 31: Structure of ∆9-THC (left) and CP 55,940 (right) 
 
 
 
 
4.3.7 Activity against free fatty acid receptor 1 (FFAR 1) 
 
Human free fatty acid receptor 1 (FFAR 1) is also known as GPR 40 and belongs to the 
family of G-protein coupled receptors. FFAR 1 is preferentially expressed in pancreatic ß-
cells and mediates the acute potentiating effect of fatty acids on glucose-stimulated insulin 
secretion, but not their chronic deleterious effects. As such, FFAR 1 is bewing considered as a 
new therapeutic target to enhance insulin secretion in type 2 diabetes mellitus. A number of 
preclinical studies and recent phase 2 clinical trials support the beneficial effects of a FFAR 1 
agonist in type 2 diabetes (Ferdaoussi 2012). Furthermore, it is probably involved by 
stimulating new memory cells in the brain, therefore also interesting for treatment of 
Alzheimer and Parkinson´s disease (Briscoe et al. 2003).  
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Figure 32: FFAR 1 assay with stemphol (3), reference TUG-424 
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assay performed by Dr. Dominik Thimm, group of Prof. Müller, University of Bonn 
 
The assay was done by measuring the intracellular concentration of calcium mobilization. 
Stemphol (3) showed a half maximal effective concentration (EC50) of 1.76 ± 0.27 µM in the 
FFAR 1 receptor assay (reference TUG-424 0.10 µM) as seen in Figure 32. Based on the 
limited agonistic activity, the next step would be the modification of the natural product 
stemphol, e.g. different alkyl chain length or the use of derivatives of stemphol to gain 
activity in the nanomolar range towards the FFAR 1 receptor. Stemphol (3) had no effect 
towards the also tested GPR 17, GPR 55 and GPR 84 receptors, respectively (see 3.6.6). 
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4.3.8 Antichlamydial activity 
 
Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium that belongs to 
the phylum Chlamydiae. It is the most prevalent cause of sexually transmitted diseases and 
the leading cause of non-congenital blindness in developing nations. Furthermore it causes 
respiratory infections, and is linked to a number of chronic diseases, e.g. asthma and 
cardiovascular disease (Bachmann et al. 2014). Up to now, no effective vaccine exists (Elwell 
et al. 2016). The parasite has a remarkable biphasic development cycle involving infection of 
the host cells by extracellular elementary bodies (EBs), transformation of EBs within the host 
cells to reticulate bodies (RBs), which are the metabolic active form. Differentiation and 
replication of the reticulate bodies followed by a transformation of RBs back to EBs, and 
release of EBs following host cell lysis complete the life cycle (Storey and Chopra 2001) and 
opens the door for further infections. 
Beside the main form of the development cycle there is another development cycle that 
includes formation of aberrant bodies (AB). Aberrant bodies can be built from reticulate 
bodies. ABs refers to an intracellular, persistent form which is built during non-ideal growth 
conditions in the host cell. It is the permanent form with reduced metabolism and can 
transform back to reticulate bodies. The aberrant bodies are in connection with reactive 
arthritis and thus of medicinal interest (Carter and Hudson 2010). 
Conducting the activity of stemphol towards the main life cycle form we investigated the 
impact of stemphol (3) towards C. trachomatis D/UW-3/CX and the host cells, respectively. 
C. trachomatis D/UW-3/CX was grown in HEp-2 host cells. Cultures were incubated for 30 h 
in the presence of serially diluted concentrations of stemphol (3), fixed with methanol and 
stained for chlamydial inclusions using fluorescein-conjugated antibodies (see 3.6.4).  
 
  Results 58 
 
Figure 33: Stemphol (3) and its inhibition of chlamydial growth in HEp-2 host cells at 
concentrations of 8 µg/ml and 16 µg/ml, respectively compared to non-infected cells 
stemphol/infected stemphol/non-infected
8 
µg
/m
l  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16
 
µg
/m
l
Red: host cell cytoplasm; blue: host cell nucleus; green: chlamydial inclusion (scale bar 20 µm)
 assay was performed by Anna Klöckner, work group of Prof. Sahl, University of Bonn 
 
Stemphol (3) showed an inhibition of chlamydial growth in a range of 8-16 µg/ml as seen in 
Figure 33. Green marked chlamydial inclusions at 16 µg/ml stemphol addition were reduced 
in quantity and size (marked in green) compared to the 8µg/ml stemphol added cells, where 
the green color is dominant within the host cells. At 16 µg/ml it is perceived that there is an 
obvious chlamydial inhibition growth as well as a partial transformation in the cytoplasm of 
the host cells. The morphology of the cell changes by increasing the cell volume. This 
phenomenon is showed as white arrows in Figure 34, an enlarged detail of Figure 33. These 
results led to the conclusion that stemphol (3) had an impact of the chlamydial growth and 
their host cells in a dose-dependent manner. Furthermore, the cytotoxic effect of stemphol (3) 
towards the host cells may also be responsible for the inhibition of chlamydial growth as seen 
in Figure 33 and Figure 34 (16 µg/ml stemphol/infected), respectively. 
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Figure 34: Enlarged detail of partial transformation by added 16 µg/ml stemphol (3) of the 
cytoplasm of the host cells (white arrows) as seen in Figure 33 
1
6
 µ
g/
m
l
Stemphol/infected
Red: host cell cytoplasm; blue: host cell nucleus; green: chlamydial inclusion (scale bar 20 µm)
 
assay was performed by Anna Klöckner, work group of Prof. Sahl, University of Bonn 
 
Besides activity of stemphol towards the main life cycle form of C. trachomatis another 
approach aimed to determine an effect of stemphol (3) towards persistent chlamydial aberrant 
bodies. Therefore, the latter assay was conducted with interferon-γ (IFN-γ) treatment of host 
cells. IFN-γ is a pro-inflammatory cytokine, which activates the expression of indoleamine 
2,3-dioxygenase. This reaction catabolizes L-tryptophan to N-formylkynurenine. Chlamydiae 
are tryptophan auxotroph and usually acquire this essential amino acid from the host. IFN-γ-
mediated depletion of tryptophan inhibits chlamydial growth and continuous exposure results 
in eradication of infection (Belland et al. 2003). These conditions gain non-ideal growth 
conditions for Chlamydiae to build the investigated aberrant bodies.   
In this assay, HEp-2 cells were cultured and then incubated with IFN-γ. Afterwards cells were 
infected with C. trachomatis with a serially diluted concentration of stemphol (3) and 
incubated for 30 h.  
 
The conducted assay additionally showed an inhibition of the chlamydial growth and the host 
cells, respectively in the same concentrations of 8-16 µg/ml as seen by the assay with the 
main form development cycle. This can be explained by a possible pronounced cytotoxicity of 
stemphol (3) towards the host cells as seen for the non-persistent chlamydial assay.  
  Results 60 
 
4.3.9 Cytotoxic activity 
4.3.9.1     Activity towards four different leukemic cell lines  
 
Stemphol (3) was tested towards four different human leukemic cell lines: chronic 
myelogenous K562 cells, immobilized human T lymphocyte Jurkat cells, hematopoietic Raji 
cells and histiocytic lymphoma U937 cells (see 3.6.8). The impact of stemphol (3) on cancer 
cells viability and proliferation is shown in Figure 36. The effect of viability and proliferation 
respectively at the indicated concentrations on the four cell lines was analyzed after 8, 24, 48, 
72 h compared to the control (Co).  
 
The calculated IC50 values of stemphol (3) towards the four different human leukemia cell 
lines (A: K562, B: Jurkat, C: Raji, D: U937) are shown in Table 12. 
 
Table 12: Calculated IC50 values of stemphol (3) towards four different human leukemia cell 
lines (A: K562, B: Jurkat, C: Raji, D: U937) 
IC50 (µM) 8h 24h 48h 72h 
A: K562 240.2 ± 59.9 54.9 ± 2.8 31.5 ± 0.8 29.1 ± 0.7 
B: Jurkat 123.1 ± 24.1 45.6 ± 2.2 33.9 ± 1.0 27 ± 0.5 
C: Raji 118.1 ± 20.4 47.4 ± 3.3 26.7 ± 0.9 18.7 ± 0.8 
D: U937 274.4 ± 70.5 60.1 ± 2.4 31.3 ± 1.0 22.6 ± 1.2 
 
Calculations were done by Seungwon Ji, work group of Prof. Diederich, Seoul National University 
 
The strongest activity was found towards Raji cells at 18.7 µM and against U937 cells at 22.6 
µM, respectively (Figure 35 and Table 12). 
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Figure 35: Effect of stemphol (3) on proliferation and viability of human leukemic cells lines (B: 
Jurkat, C: Raji, D: U937, Co: control) 
 
 
 
Additionally the effect of stemphol (3) on NF-κB activity was investigated. NF-κB is a family 
of closely related protein dimers, a key transcription factor, which is involved in regulating, 
amongst other, proliferation of cancer cells and lead to expression of target genes involved in 
all steps of tumorigenesis. Therefore, it became a promising therapeutic target of 
hematological malignancies and solid tumors. In collaboration with the workgroup of Prof. 
Diederich, Seoul National University, we investigated the effect of stemphol (3) on TNFα, a 
tumor necrosis factor, a cytokine that is involved in inflammation and in regulation of 
immune cells and apoptotic cell death. Evidence further indicates strong association between 
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chronic inflammatory conditions and cancer (Coussens and Werb 2002). Stemphol (3) 
showed an inhibition of NF-κB activity in four different leukemia cell lines in a dose 
dependent manner. Thus, stemphol (3) inhibited TNFα-induced NF-κB activity with an IC50 
of 18 µM in Jurkat and 30 µM in U937, respectively (Figure 36). 
 
Figure 36: Inhibitious effect of stemphol (3) on TNFα-induced NF-κB activity in (B) Jurkat and 
(D) U937 cells in a dose-dependent manner; Co: control, GTN: goniothalamin (positive control) 
 
Each graph corresponds to the mean ± SD of three independent experiments. * indicate p< 0.05 compared to control negative group, assay 
was done by Seungwon Ji, work group of Prof. Diederich, Seoul National University 
 
NF-κB regulates at least 500 genes (Faustman and Davis 2010). Therefore, the focus on the 
further studies was to narrow down the signaling pathway, in which stemphol (3) is involved. 
The origin of cancer involves deregulated cellular proliferation and the suppression of 
apoptotic processes, ultimately leading to tumor establishment and growth. Caspases, which 
are an acronym for cysteine-aspartic proteases, cysteine aspartases and cysteine-dependent 
aspartate-directed proteases, respectively, are playing an essential role in programmed cell 
death.  
Therefore, the next step was an assay with the caspase inhibitor zVAD. zVAD is a synthetic 
peptide-inhibitor, who contains the obligate amino acid aspartate at the C-terminal. Within the 
inhibitor is a benzyloxycarbonylgroup, whereby zVAD can bind nonspecific on the active 
center on every caspase. The consequence is direct and irreversible inhibition of the caspases 
(Bauhammer 2005). After addition of the caspase inhibitor zVAD and serially diluted 
amounts of stemphol (3), U937 cancer cells are stained with propodium Iodide (Pi). Pi is an 
intercalating agent and a fluorescent molecule which is used to stain membrane-disrupted 
cells for the assay analysis. At early stage of the apoptosis it is not possible to stain the cells. 
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Therefore, for these cells the dark grey color was chosen including the term Pi negative / 
apoptotic (Figure 37). Healthy cells were also unable to stain and therefore marked as Pi 
negative / non-apoptotic in light grey color. Correspondingly, the term Pi positive / apoptotic 
colored in black was used for membrane-disrupted cells and the term Pi positive / non-
apoptotic colored in white and black was used for dead cells built by other than the apoptotic 
pathway e.g. necrosis (Figure 37).  
 
 
Figure 37: Stemphol (3) induced caspase-independent U937 cell death at 24 h in a dose-
dependent manner, Etoposide (Eto) - positive control, zVAD - caspase inhibitor, Pi -propodium 
iodide 
 
assay was done by Seungwon Ji, work group of Prof. Diederich, Seoul National University 
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Figure 38: Enlarged picture of Etoposide (left) - positive control - and stemphol 30 µM (right) 
treated U937 cells - nuclear fragmentation marked as red arrows, chromatin condensation 
marked as white arrows, respectively 
 
assay was done by Seungwon Ji, work group of Prof. Diederich, Seoul National University 
 
 
The zVAD assay revealed that there is a stemphol-induced cell death even in the presence of 
caspase inhibitor zVAD in a dose-dependent manner. In figure 38 Etoposide, the positive 
control, leads to apoptosis of the cancer cells. After 24 h, more than 10% of the cells reached 
apoptosis whereas most of the rest is in an early stage of the apoptosis. At this stage Pi is not 
able to stain the cells, therefore the term Pi negative / apoptotic is used. By addition of the 
caspase inhibitor zVAD, 60 % of the cells are still alive after 24 h whereas 30% are on an 
early stage of apoptosis and 10 % are membrane-disrupted (Pi positive) non apoptotic cells, 
probably necrotic cells. Starting from 30 µM stemphol (3) quantity of living cells (marked as 
Pi negative / non apoptotic in light grey color) decrease while the amount of apoptotic cells, 
induced by stemphol (3) and independent to zVAD significantly increase (marked as Pi 
negative / apoptotic in dark grey color). This effect is also seen by 50 µM and 70 µM addition 
of stemphol (3), independently of the addition of the caspase inhibitor zVAD (Figure 37). 
Typical for apoptosis are morphological changes such as nuclear fragmentation or chromatin 
condensation. These phenomenon is seen in Figure 39 for the positive control Etoposide (left) 
and the added 30 µM stemphol (right), marked as red arrows and white arrows, respectively. 
The purple colored cells in Figure 38 (right) are membrane-disrupted and therefore Pi positive 
cells.  
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4.3.9.2     Activity towards reactive oxygen species 
 
Reactive oxygen species (ROS) are constantly generated and eliminated in the biological 
system and are required to drive regulatory pathways e.g. they are one of the NF-κB inducing 
factors. By interferences of the usual equilibrium of intracellular mitochondrial produced 
ROS and eliminated reactive oxygen species through scavenging systems like antioxidants 
excessive ROS can damage lipids, proteins and DNA, which led to fatal lesions in cell and 
can implicate pathogenisis of cancer (Droege 2002). Therefore, the effect of stemphol (3) 
towards ROS provides a possibility for deeper investigations of the inhibition pathway 
through the isolated metabolite. During the cellular detection assay (DCFDA) stemphol (3) 
showed an antioxidant effect (Figure 39). 30 µM of Stemphol (3) inhibited significantly 
intracellular ROS level of 50 % after 30 min and of 60 %  after 4 hours respectively (see 
3.6.9).   
 
 
Figure 39: Cellular reactive oxygen species detection assay (DCFDA) of stemphol (3) after 30 
min (A) and 4 hours (B) 
 
Each graph corresponds to the mean ± SD of three independent experiments. , *, ** indicate     p< 0.05, p < 0.01 compared to control 
negative group, respectively, assay was done by Seungwon Ji, work group of Prof. Diederich, Seoul National University 
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4.4 Further metabolites isolated from Stemphylium globuliferum 
 
4.4.1 New natural product 4-butyl-3,5-dihydroxy benzoic acid (4) 
4.4.1.1      Cultivation and extraction of 4-butyl-3,5-dihydroxy benzoic acid (4) 
 
4-butyl-3,5-dihydroxy benzoic acid (4) was isolated from the endophytic fungus St. 
globuliferum. After homogenization and extraction of the fungal biomass and BMS-media 
with EtOAc 1.7 g of crude extract were obtained. The material was fractionated employing 
NP-VLC (0.063-0.200 mm, Merck) using stepwise elution from petrolether to EtOAc to 
MeOH to afford 11 fractions. Of these, fraction 1.3 was further separated via another NP-
VLC (0.040-0.063 mm, Merck) using stepwise elution from petrolether to EtOAc of which 
the subfractions 1.3.7 and 1.3.8 were collected and reunited. 4-butyl-3,5-dihydroxy benzoic 
acid (4) was finally isolated via an RP-HPLC fractionation to yield 1.2 mg (Figure 40). 
 
 
Figure 40: Structure of 4-butyl-3,5-dihydroxy benzoic acid (4) 
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4.4.1.2 Structure elucidation of 4-butyl-3,5-dihydroxy benzoic acid (4) 
 
Table 13: NMR spectroscopic data (300 MHz) of 4-butyl-3,5-dihydroxy benzoic acid (4) in 
MeOH-d4 
Pos. 
δH, in ppm, mult., 
J (Hz) 
δC in ppm 
1H-1H COSY-
Correlations 
HMBC-Correlations 
1 
 
170.5, C 
  
2a 
 
157.3, C 
  
2b 
 
157.3, C 
  
3 
 
130.0, C 
  
4 
 
122.9, C 
  
5a 7.00, brs 108.8, CH 
 
C-2, C-3, C-4, C-5b 
5b 7.00, brs 108.8, CH  C-2, C-3, C-4, C-5a 
6 
 
1.53, m 32.1, CH2 
H2-7 
 
C-4, C-8 
7 2.67, tr (7.5) 24.1, CH2 H2-6 C-2, C-4, C-6, C-8 
8 1.44, m 23.9, CH2 H3-9 C-6 
9 0.94, tr (7.4) 14.4, CH3 H2-8 C-6, C-8 
 
The 13C-NMR and DEPT-135 spectra showed 11 resonances for one methyl group, three 
methylene and two methine groups, as well as five quaternary carbon atoms. Functional 
groups within the molecule could be deduced from 13C-NMR signals, for one carboxylic acid 
at δ 170.5 (C-1) and two hydroxylated carbon atoms at δ 157.3 (C-2a and C-2b) (Table 13). 
Analysis of the 1H-1H COSY spectrum allowed to delineate a spin-system including H-6 to H-
9 pointing towards a butyl chain. The analysis of the 1H-13C-HMBC spectrum showed the 
presence of a benzene ring. HMBC correlations of H2-7 to C-2, C-4, C-6 and C-8 indicated 
that the butyl chain must be connected via C-4 to the benzene ring. This assumption is 
supported by correlations of H2-6 to C-4 and C-8. Taking the molecular formula into account, 
two hydroxyl groups and a carboxylic acid still have to be connected. The hydroxyl groups 
are attached to C-2a and C-2b, respectively, the carboxylic acid is connected to C-3. This is 
supported by the 13C-NMR chemical shifts of these carbons.  
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4.4.1.3    Antibacterial activity of 4 
 
4-butyl-3,5-dihydroxy benzoic acid (4) was tested against a broad spectrum of 
microorganisms, that is, the Gram-positive bacteria Staphylococcus aureus 133, Bacillus 
subtilis 168, Micrococcus luteus 4698, Arthrobacter crystallopoietes DSM 20117, the Gram-
negative bacteria Escherichia coli I-11276b, Klebsiella pneumoniae subsp. ozeanae I-10910 
and the fungus Candida albicans I-11301. The compound revealed a moderate antibiotic 
activity against E coli with an inhibition of 3 mm (3µg/assay). The test was performed by 
Michaele Josten from the group of Prof. Tanja Schneider, Institute of Pharmaceutical 
Microbiology, University of Bonn.  
 
4-butyl-3,5-dihydroxybenzoic acid (4) 
C11H14O4 (210.23) 
(3.6 mg)    
0.36mg/L 
 
4.4.2 Infectopyrone (5) 
 
Fungal biomass and Malt-yeast media were homogenized and extracted with EtOAc to yield 
1.9 g of the extract. The material was fractionated employing NP-VLC (0.063-0.200 mm, 
Merck) using stepwise elution from petroleum ether to EtOAc to MeOH to afford 23 
fractions. Of these, fraction 10 (250 mg) was achieved by RP-HPLC (Eurosphere C18 
MeOH/H2O = 80/20) to afford 17 mg of subfraction 2.10.5 (Figure 41).  
 
Figure 41: Structure of infectopyrone (5) 
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Compound 5 was isolated and identified as the α-pyrone derivative infectopyrone (Larsen et 
al. 2003).  
C14H16O5 (264.27) 
1.5 mg/L 
Pale yellow amorphous solid (15 mg) 
- no antimicrobial activity 
- no cytotoxicity 
- no inhibition of Chlamydia 
- no anti-parasitic activity 
- no NF-κB inhibition   
 
 
 
 
4.4.3     Stemphypyrone (6) 
 
Stemphypyrone (6) was isolated from the endophytic fungus St. globuliferum. After 
homogenization and extraction of the fungal biomass and media with EtOAc 1.7 g of crude 
extract were obtained. The material was fractionated employing NP-VLC (0.063-0.200 mm, 
Merck) using stepwise elution from petrolether to EtOAc to MeOH to afford 11 fractions. Of 
these, fraction 1.3 was further separated via another NP-VLC (0.040-0.063 mm, Merck) using 
stepwise elution from petrolether to EtOAc of which the subfractions 1.3.7 and 1.3.8 were 
collected and reunited. Stemphypyrone (6) was finally isolated via an RP-HPLC (Knauer C18 
Eurospher-100 MeOH/H2O = 55/45) fractionation to yield 2.8 mg (Figure 42). 
 
Figure 42: Structure of stemphypyrone (6) 
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Compound 6 was isolated as stemphypyrone according to Debbab et al. 2009 
C12H16O4 (224.25) 
Red powder (2.8 mg) 
0.28 mg/L 
- no antimicrobial activity 
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5.        Discussion 
Fungi are a ubiquitously occurring group of organisms. They were shown to be a superior 
source for structurally new and biologically active compounds, which is reflected by the ever 
increasing number of published literature dealing with fungal secondary metabolites (Zheng 
et al. 2016; Newman und Cragg 2016).  
The here investigated organism Stemphylium globuliferum is a mold fungus and belongs to 
the Pleosporaceae. Stemphylium spp. is known for their phytopathogenity. Thus, the focus of 
former research targeted the prevention of agricultural damages, e.g. the Stemphylium leaf 
spot disease or the purple spot disease on Asparagus officinalis (Graf et al. 2016). Isolated 
metabolites, i.e. stemphyloxin I and II (Figure 43) as well as stemphol (Figure 24) confirmed 
this phytotoxicity in that they cause damage to leaves (Barash et al. 1982; Manulis et al. 
1984). Beyond these compounds, the species is known for, e.g. the cytotoxic compound 
altersolanol A (Teiten et al. 2013) (Figure 7, introduction).   
In the present study, S. globuliferum was isolated for the first time from the marine-derived 
alga Petalonia zosterifolia, and thus the fungus originated from the - in general - 
underexplored marine habitat. The secondary metabolites isolated from our marine fungal 
strain possess interesting pharmacological activities useful for further developments, and at 
the same time give insights into chemistry of fungi from a poorly investigated area.  
Six metabolites were obtained from this fungus. Stemphol (3) and 4-butyl-3,5-dihydroxy 
benzoic acid (4) are known resorcinol-derivatives, whereas stemphylofuran (2) has a new 
unprecedented structure composed of a furan ring and a 3-pentenone moiety. Stemphypyrone 
(6) and infectopyrone (5) have a α–pyrone core structure and are described in the literature 
(Debbab et al. 2009; Larsen et al. 2003), while the novel stemphyloxin III (1) is a decline-
based metabolite with structural similarities to the known, polyketides stemphyloxin I and II 
(Barash et al. 1982; Larsen et al. 2003), respectively.   
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Figure 43: The plant toxic compounds stemphyloxin I (left) and II (right) from 
Stemphylium spp. 
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5.1        Discussion of the new metabolite stemphyloxin III (1) 
 
The new metabolite stemphyloxin III (1) is closely related to the polyketides stemphyloxin I, 
probetaenone I and a coincenal D-derivative, which are all of fungal origin (Figure 44). All of 
these compounds are described as biologically active. Betaenone type compounds like 
probetaenone I are known as phytotoxins, but also inhibit protein kinase, e.g. CDK4-kinase 
and therefore of particular interest for the development of new anticancer drugs (Ichihara et 
al. 1983; Brauers et al. 2000). Stemphyloxin I is also toxic towards plants (Manulis et al. 
1984). Coicenal D, firstly isolated from the plant pathogenic fungus Bipolaris coicis, has 
moderate nitric oxide (NO) inhibition potential, pointing to a possible therapeutic value in 
inflammatory diseases (Wang et al. 2013).  
Agar diffusion assays revealed that 1, isolated during the current study, leads to growth 
inhibition of Micrococcus luteus and Arthrobacter crystallopoietes with 5 mm and 7 mm 
inhibition zones (3 µg), respectively, whereas no activity towards other groups of 
microorganisms could be detected (see 3.5.1). These results are similar to the ones obtained 
for coicenal D (Wang et al. 2013). Additionally, no cytotoxic effect up to 30 µM for 1 could 
be observed.    
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Figure 44: Structures of the decaline-derivatives stemphyloxin III (1), stemphyloxin I, a 
coincenal D-derivative and probetaenone I 
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The decaline core structure of 1 and the secondary butyl moiety are alike to those of 
probetaenone I. At C-5 however, stemphyloxin III (1) is linked to a succinyl unit, which is 
missing in probetaenone I. In turn, the latter moiety is identical to that of a coincenal D-
derivative described in the literature (Wang et al. 2013), where also a succinyl unit is attached 
to the decaline core structure. Furthermore, stemphyloxin III (1) has an enol functionality 
attached to C-1, which is alike that in stemphyloxin I, except the fact, that the here isolated 
natural product has merely a methoxy group at C-11, whereas the known toxin has a hydroxyl 
group (Figure 44). In the latter case the enol functionality can be regarded as a tautomeric 
form of an aldehyde group.  
Future perspectives for the isolated new metabolite stemphyloxin III (1) can be the 
derivatization to enhance the bioactive potential of the new natural product.  
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Figure 45: Betaenone A, B and C from the fungus Phoma betae 
 
 
The biosynthesis of stemphyloxin III (1) may be related to the betaenone pathway from the 
fungus Pleospora betae (Ugai et al. 2015), a plant pathogen producing the known phytotoxins 
betaenone A, B and C (Figure 45). Based on the results for betaenones, a biosynthesis for 
stemphyloxin III (1) can be assumed as shown in Figure 46. Thus, the building blocks 
malonyl-CoA, acetyl-CoA and S-adenosyl-methionin (SAM), may form a linear polyketide 
chain in that the starter unit acetyl-CoA is connected with the malonyl-CoA units. 
Ketoreductases, dehydratases and enoylreductases modify the chain during chain elongation 
and a linear polyketide as shown in Figure 46 is generated. After the reductive chain-release 
to form the enol moiety on the C-terminal ending a [4+2] cycloaddition (Diels-Alder-reaction) 
of the alkyl chain leads to trans-decaline skeleton. The latter mechanism is similar to one 
observed for the well-studied fungal polyketide lovastatin, where also a [4+2] cycloaddition 
takes place (Ma and Tang 2007). After the cyclization follows a presumable methylation of 
OH-12 by an oxygen-methyltransferase, as well as the transfer of the succinic acid moiety to 
the hydroxyl group at C-5, to build the new natural product stemphyloxin III (1).  
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Figure 46: Proposed biosynthetic pathway of stemphyloxin III (1) 
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5.2       Discussion of the new metabolite stemphylofuran (2) 
 
Furan rings offen occur in natural products, and form a diverse group of biologically active 
compounds. Some of them shall be mentioned. The plant-derived salvinorin A from Salvia 
divinorum is a psychotropic molecule and has a long history of use as an entheogen by 
indigenous Mazatec shamans. Furthermore, limonin has a furan moiety and activity towards 
colon cancer cells, as well as being positive in a test against obesity in mice (Chidambara et 
al. 2011; Ono et al. 2011). The sponge-associated fungus Hypocrea koningii contains 
hypofuran A, which has radical scavenging properties (Ding et al. 2015) (Figure 47). Another 
example for furan-derivatives is the recently discovered murranofuran A from the endophytic 
fungus Culvularia sp. isolated from the curry plant Murraya koenigii (Mondol et al. 2017).  
 
Figure 47: Furan-derivatives hypofuran A, left; salvinorin A, middle; limonin, right 
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The here investigated stemphylofuran (2) is a furan-derivative with a 3-pentenone moiety, 
connected via a methine group to a furan ring (Figure 17). This carbon skeleton is a rare 
structural feature and only found in phellinusfuran A from the fungus Phellinus linteus 
(Figure 48). Beside data for the structure elucidation, no literature towards biological activity 
could be found for phellinusfurans. Stemphylofuran (2) is structurally similar phellinusfuran 
A (Min et al. 2006). It is remarkable that both metabolites were gained from alga-derived 
fungi, hinting towards some correlation to the unique saltwater habitat.  
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Figure 48: Stemphylofuran (2) and phellinusfuran A 
 
 
The new isolated metabolite 2 was tested against a variety of microorganisms. 
Stemphylofuran (2) showed antimicrobial activity towards Micrococcus luteus and 
Arthrobacter crystallopoietes of 3 mm and 5 mm, respectively, whereas no activity towards 
other groups of microorganisms could be detected. Additionally, no cytotoxic effect up to 30 
µM of 2 could be observed. 
 
5.3.      Discussion of the metabolite stemphol (3) 
 
Stemphol (3) is a 2,5-dialkylresorcinol, firstly isolated from S. majusculum in 1973 (Stodola 
et al. 1973) (Figure 49). Beside significant inhibitory activity towards the phylogenetically 
related fungus Pleospora herbarum, it showed antimicrobial effects against Gram-positive 
bacteria, a plant pathogenic fungus and a yeast (Achenbach et al. 1979). Resorcinol itself and 
its mono and dialkylated derivatives display a broad spectrum of biological activities, e.g. 
resorcinol is used for the treatment of psoriasis, the monoalkylated 4-hexylresorcinol 
significantly decreased the tumor growth rate in mice, and 2,5-dialkylated DB-2073 (Figure 
8), was found active against mycobacteria, yeasts, fungi and Gram-positive bacteria (Kanda et 
al. 1975). 
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Figure 49: Structure of stemphol (3) isolated from S. globuliferum 
 
 
Our experiments addressing the antimicrobial activity of stemphol (3) comfirmed the data in 
the literature, i.e. activity towards Gram-positive bacteria (Achenbach et al. 1979). Beyond 
that, we noticed that not only S. aureus but also methicillin-resistant S. aureus was inhibited 
with a MIC value of 4 µg/ml. Furthermore, inhibition of E. faecium and K. pneumoniae with 
MICs of 16 µg/ml and 64 µg/ml, respectively underlined the antibacterial potential of 
stemphol (3). These microorganisms are within the group of “ESKAPE” pathogens (E. 
faecium, S. aureus, K. pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species) accentuating their capacity to “escape” from routine antimicrobial 
drugs (Khan and Khan 2016). Multidrug resistance is amongst the top three threats to global 
public health and can be caused by inappropriate use or excessive use of drugs (Santajit et al. 
2016). The inhibition of three of these organisms through stemphol (3) is remarkable and may 
lead to further research in this discipline. 
 
However, structure-activity relationships for the antimicrobial activity are not verified yet. 
Achenbach et al. only showed that a molecule with two pentyl chains, i.e. in C-2 and C-5 
position of the benzene ring, have no activity towards B. subtilis, S. aureus, as well as 
Schizosaccharomyces pombe and Mucor hiemalis, whereas a molecule with a pentyl chain in 
C-2 position and a butyl chain in C-5 position was inhibitory against all four tested organisms 
(Achenbach et al. 1979, 1979).  
 
Stemphol (3) was shown by us to lead to a diminished number of chlamydia in Hep-2 host 
cells (see. 4.3.8). During the assays it was noted, that the cell line in which the chlamydia 
grow was also affected by stemphol (3). Thus, the results of stemphol (3) towards the tested 
chlamydial organisms reveal that the potential of inhibition of these pathogens can be based 
on cytotoxic effects of 3 towards the host cells. This possible indirect inhibition can be an 
explanation for the partial transformation of the chlamydial host cells at 16 µg/ml (see 4.3.8). 
The morphological changes and thereby the increase of the cell volume revealing the stressful 
conditions for the host is due to the addition of the fungal metabolite (3).  
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The cytotoxicity can also be a reason for the weak selectivity of 3 towards the investigated 
protozoan parasites Trypanosoma brucei rhodesiense, T. bruzi, Leishmania donovani and 
Plasmodium falciparum. A good example for this are the results obtained for the inhibition of 
L. donovani, for which only a selectivity index of 15 was calculated, which is a weak value 
compared, e.g. palmarumycin CP18 from the endophytic fungus Edenia sp. with 245 times 
more antileishmanial activity than cytotoxicity (Figure 50) (Martinez-Luis et al. 2008). 
Derivatization of stemphol (3) can be an approach to gain a reduced cytotoxicity and an 
increase of selectivity, and may open the door for further drug development using the isolated 
fungal alkylresorcinol-derivative (3).   
 
Figure 50: Palmarumycin CP18 from the endophytic fungus Edenia sp. 
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Additionally, the free radical scavenging potential of stemphol (3) was tested using a reactive 
oxygen species assay (see 4.3.9.2), which showed that stemphol (3) has antioxidant potential 
as known of dialkylresorcinols, e.g. the derivatives DB-2073 and resorstatin (Figure 8, 
introduction) have free radical scavenging potential (Kato et al. 1993). 
 
Furthermore, cytotoxicity assays against the four different cancer cell lines K562 cells, Jurkat 
cells, Raji cells and U937 cells, respectively, were done with the isolated metabolite (3). The 
assays revealed that stemphol (3) has a growth inhibitory activity towards these cell lines, 
even though the inhibition is weaker when compared to other natural products, e.g. 13 times 
weaker than for altersolanol A (Figure 7, introduction). Altersolanol A, which is also 
inhibiting the NF-κB transcriptional activity, as was shown for stemphol (3), possesses a p-
quinone moiety possibly related to the bioactivity. Stemphol (3) however is merely a phenolic 
metabolite, of which a metabolic transformation to a quinone cannot be excluded. Stemphol 
(3) inhibited the TNFα-induced NF-κB pathway in a capase-independent manner. 
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Furthermore, it shows specific morphological changes such as chromatin condensation in 
U937 cells hinting at a non-canonical pathway. The caspase independent inhibition of the NF-
κB pathway through stemphol (3) making this isolated metabolite a valuable target for deeper 
investigations regarding anti-cancer drug development. Arisawa et al. showed that anticancer 
activity is based on hydroxylation of the benzene ring on C-1 and C-3, respectively, as well as 
C-5 medium length alkyl chain. The fact that methylated and acetylated derivatives of the 
hydroxylated benzene ring were inactive pointed to the importance of the hydroxyl groups 
(Arisawa et al. 1989). 
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6.    Summary  
Fungi are a tremendous source of pharmaceutically significant compounds, e.g. the life saving 
immunosuppressant drug mycophenolic acid. The current project focused on the investigation 
of the mold fungus Stemphylium globuliferum obtained from the marine alga Petalonia 
zosterifolia, with the aim to find natural products with novel chemical structures and 
prominent pharmacological activities, particularly antibiotic and/or anticancer effects. 
 
The fungus was cultivated on potato-dextrose-medium and found to produce strongly active 
antimicrobial metabolites. Subsequently, the extract was separated by vacuum liquid 
chromatography using a gradient elution system, as well as optimized HPLC separations. Six 
metabolites were obtained in pure form and characterized using spectroscopic methods. 
Stemphyloxin III (1) has structural similarities to the known stemphyloxins I and II, 
respectively, but differs concerning the moiety at C-5, where stemphyloxin III (1) has a 
linkage to a succinyl unit. Furthermore, the enol group at C-1 of stemphyloxin III (1) is 
methylated, whereas stemphyloxin I has no methylation on this functional group. Concerning 
the biosynthesis of 1, a polyketide origin is most likely, as proven for the structurally closely 
related betaenones.  
Compound 1 showed moderate antibacterial activities towards Arthrobacter crystallopoietes 
and Micrococcus luteus (agar diffusion assay, inhibition zone of 7 mm for A. crystallopoietes, 
5 mm for M. luteus at 3µg, respectively).  
 
The second new compound proved to be stemphylofuran (2), a structurally most unusual 
metabolite consisting of a cyclic pentenone moiety connected via a methine bridge to a furan 
ring.  Due to the presence of four quaternary carbons in the cyclopentenone the structural 
assignment of this part of the molecule was a challenge that could finally be solved by NOE 
measurements. Correlations of H-7 to H3-14 in these measurements clearly pointed towards a 
cyclopentenone structure instead of an alternatively assumed six membered ring. This new 
metabolite showed limited antibacterial activities towards A. crystallopoietes and M. luteus 
(agar diffusion assay, inhibition zone of 5 mm for A. crystallopoietes, 3 mm for M. luteus at 
3µg, respectively).  
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The prominent antimicrobial activity of the fungal extract could be traced back to the known 
metabolite stemphol (3), which showed antimicrobial effects towards methicillin-resistant 
Staphylococcus aureus and S. simulans with MIC values in both cases of 4 µg/ml, as well as 
against Candida albicans with an MIC value of 4 µg/ml. Stemphol (3) also had weak 
activities against the Gram-positive Enterococcus faecium and Klebsiella pneumoniae subsp. 
ozeanae with MIC values of 16 µg/ml and 64 µg/ml, respectively. Against Gram-negative 
bacteria only a weak activity was noted. From these results, stemphol (3) may be considered 
as an active agent against problematic Gram-positive pathogens.  
 
Furthermore, stemphol (3) was tested for its antichlamydial activity. Therefore, HEp-2 host 
cells were infected with Chlamydia trachomatis D/UW-3/CX. After gaining chlamydial 
inclusions in the host cells, the test system was incubated with serially diluted concentrations 
of stemphol (3).  It inhibited chlamydial growth in the range of 8 to 16 µg/ml, but also had a 
pronounced cytotoxicity towards the host cells at high stemphol concentrations. This 
cytotoxic activity was investigated further using four different human cancer cell lines 
(Jurkat, Raji, U937 and K562 cell lines), which yielded IC50 values for stemphol of 18.7 ± 0.8 
µM towards Raji cells and 22.6 ±1.2 µM towards U937 cells, respectively. Additionally the 
effect of stemphol (3) towards NF-κB was examined and revealed, that TNFα-induced NF-κB 
activity was inhibited with an IC50 of 18 µM in Jurkat cells and 30 µM in U937 cells, 
respectively. Overall, our results point towards a caspase-independent TNFα-induced NF-κB 
inhibition, making this metabolite interesting in the search for new cancer therapies.  
 Summary   
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Stemphol (3) revealed limited activity against parasites, e.g. Trypanosoma brucei subsp. 
rhodesiense and Leishmania donovani with IC50 values of 0.18 µg/ml and 0.30 µg/ml, 
respectively, but again had pronounced cytotoxicity towards the control myoblast cells, 
showing the limited selectivity of the fungal metabolite. Radioligand binding studies revealed 
that 3 had weak affinity towards the cannabinoid receptors CB1 and CB2. In contrast, the 
resorcinol-derivative 4-butyl-3,5-dihydroxy benzoic acid (4) was not active toward CB 
receptors,which may be explained by the alkyl chain of stemphol (3) at C-5 instead of a 
carboxylic acid group at C-5 in the case of 4-butyl-3,5-dihydroxy benzoic acid (4). 
Furthermore, stemphol (3) showed agonistic activity (EC50 = 1.76 ± 0.27 µM) at FFAR 1 
receptor, but no effects towards GPR 17, GPR 55 and GPR 84 receptors, respectively.   
 
In conclusion, this project led to the new natural products stemphyloxin III (1), 
stemphylofuran (2) and 4-butyl-3,5-dihydroxy benzoic acid (4) as well as the known 
compounds stemphol (3), infectopyrone (5) and stemphypyrone (6). Their antibacterial, 
antifungal, antiplasmodial and cytotoxic activities, and furthermore their affinity toward CB1, 
CB2 and on FFAR1 receptors, respectively, showed the broad pharmacological potential of 
the gained metabolites.  
The results of this study demonstrate that the mold fungus Stemphylium globuliferum is able 
to produce novel and promising lead structures for further pharmacological research and drug 
development based on natural products.   
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8.     Appendix 
8.1 NMR, UV and IR spectra of the isolated compounds 
Figure 51: 1H-NMR spectrum of stemphyloxin III (1) in MeOD (600 MHz) 
 
Figure 52: 13C-NMR spectrum of stemphyloxin III (1) in MeOD (150 MHz) 
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Figure 53: UV spectrum of stemphyloxin III (1) in MeOH 
  
 
 
Figure 54: IR spectrum of stemphyloxin III (1) in Acetone-d6 
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Figure 55: 1H-NMR of stemphylofuran (2) in MeOD (600 MHz) 
 
 
Figure 56: 13C-NMR spectrum of stemphylofuran (2) in MeOD (150 MHz) 
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Figure 57: UV spectrum of stemphylofuran (2) in MeOH 
 
 
Figure 58: IR spectrum of stemphylofuran (2) in Acetone-d6 
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Figure 59: 1HNMR of stemphol (3) in MeOD (300 MHz) 
 
 
Figure 60: 13CNMR of stemphol (3) in MeOD (75 MHz) 
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Figure 61: UV spectrum of stemphol (3) in MeOH 
 
 
Figure 62: 1H-NMR spectrum of 4-butyl-3,5-dihydroxy benzoic acid (4) in MeOD (300 MHz) 
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Figure 63: 13C-NMR spectum of 4-butyl-3,5-dihydroxy benzoic acid (4) in MeOD (75 MHz) 
 
Figure 64: UV spectrum of 4-butyl-3,5-dihydroxy benzoic acid (4) in MeOH 
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Figure 65: IR spectrum of 4-butyl-3,5-dihydroxy benzoic acid (4) in Acetone-d6 
 
 
 
